CD40L antagonists and uses thereof

CD40L-specific Tn3 scaffold proteins fused to HSA provide a safer alternative to anti-CD40L antibodies by inhibiting CD40/CD40L interactions, effectively treating autoimmune diseases with reduced thromboembolic risks.

JP7596261B2Active Publication Date: 2024-12-09VIELA BIO INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021516965
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-28
Filing Date
2019-09-25
Publication Date
2024-12-09
Estimated Expiration
2039-09-25

AI Technical Summary

Technical Problem

Existing therapies targeting the CD40/CD40L pathway for autoimmune diseases, such as anti-CD40L monoclonal antibodies, face adverse thromboembolic events due to interactions with FcγRIIa on platelets, necessitating the development of safer alternatives.

Method used

The use of CD40L-specific Tn3 scaffold proteins fused to human serum albumin (HSA) to block CD40/CD40L interactions, inhibiting B cell activation and differentiation without inducing platelet aggregation.

Benefits of technology

VIB4920 effectively reduces clinical symptoms and disease markers in autoimmune diseases like rheumatoid arthritis by suppressing B cell and T cell immune responses, with a favorable safety profile and reduced adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596261000003
    Figure 0007596261000003
  • Figure 0007596261000004
    Figure 0007596261000004
  • Figure 0007596261000005
    Figure 0007596261000005
Patent Text Reader

Abstract

Human CD40L-specific Tn3 molecules and their therapeutic uses.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] The CD40 / CD40L pathway plays an important role in triggering humoral immune responses and is involved in the pathogenesis of several autoimmune diseases. CD40 is constitutively expressed on a variety of antigen-presenting cells, including dendritic cells (DCs), macrophages, and B cells (1), and can also be expressed on nonhematopoietic cells.

[0002] Expression of the CD40 ligand, CD40L (also known as CD154), is highly regulated and found predominantly on activated CD4+ T cells (2). CD40 / CD40L interactions between B cells and activated T cells are essential to mount effective humoral responses to T cell-dependent antigens (3-5). The CD40 / CD40L system drives B cell proliferation, differentiation, and isotype switching in vitro (6-9). In vivo, CD40 signaling is required for germinal center (GC) formation, somatic hypermutation, and the generation of memory B cells and long-lived plasma cells (10-13). Deficiency of CD40 or CD40L in humans results in X-linked hyperimmunoglobulin syndrome, a disease characterized by impaired isotype class switching, manifested as high levels of serum IgM with low to no detectable IgG, IgA, or IgE and increased susceptibility to infections (14-16).

[0003] Clinical trials with compounds directed against CD40L have demonstrated the potential efficacy of targeting the CD40 pathway in autoimmune diseases. In a phase 2 study, the humanized 5c8 anti-CD40L antibody BG9588 significantly reduced proteinuria and anti-dsDNA antibody titers in patients with proliferative lupus nephritis (17). Treatment with anti-CD40L reduced the circulating CD38 antibody levels present in patients with active SLE. hiFurther studies have demonstrated that Ig-secreting cells, as well as peripheral GC B cells, are depleted (18, 19), and treatment with anti-CD40L monoclonal antibodies (mAbs) has been shown to induce significant responses in a subset of patients with immune thrombocytopenia (ITP) (20).

[0004] Despite the potential of anti-CD40L mAb treatment in clinical trials, these programs have been halted due to adverse thromboembolic events. One possible explanation for these unexpected safety issues, although not precisely defined, is the expression of FcγRIIa (or CD32a) on platelets, which is expressed in humans but not in mice (21). CD40L is also highly expressed on activated platelets (22) and may trigger platelet aggregation through simultaneous antibody-mediated binding to both CD40L and FcγRIIa on neighboring cells. Mouse models support the role of FcγRIIa in anti-CD40L-induced thrombocytopenia. In transgenic mice that introduced human FcγRIIa, anti-CD40L mAb caused shock and thrombocytopenia (23). This effect was not observed in either wild-type mice unable to engage FcγR or in transgenic mice injected with an aglycosylated version of the antibody.

[0005] To target CD40L but without the potential complications associated with mAbs, a CD40L-specific Tn3 scaffold protein (24, 25) was generated. The Tn3 protein is derived from the third fibronectin type III domain of human tenascin-C and can be modified to confer target-specific binding properties (26, 27). Fusing the bivalent CD40L-specific Tn3 protein to human serum albumin (HSA) yielded a molecule, VIB4920, that could bind human CD40L and block its interaction with the CD40 receptor. Consistent with this inhibition of CD40L / CD40 interaction, VIB4920 was able to potently inhibit human B cell activation and differentiation in vitro by blocking CD40 signaling events.

[0006] There is a need in the art for new therapeutic approaches to significantly affect the humoral immune response and treat autoimmune and / or inflammatory conditions, as well as to induce immune tolerance into replacement therapy in patients in need thereof.

[0007] VIB4920 has now been shown to reduce clinical symptoms and other markers of disease when administered to patients suffering from autoimmune / inflammatory diseases or disorders. In particular, administration of VIB4920 at specific doses to subjects with rheumatoid arthritis (RA) results in statistically significant reductions in disease activity as measured by rheumatoid factor (RF) autoantibody titers, Vectra DA biomarker scores, and DAS28-CRP compared to placebo. Summary of the Invention [Means for solving the problem]

[0008] Provided herein is a method for suppressing B cell and T cell mediated immune responses in a subject, the method comprising administering to a subject in need thereof a dose of 500 mg to 3000 mg of VIB4920 to suppress B cell and T cell mediated immune responses.

[0009] The present specification also provides a method for treating an autoimmune disease or disorder, the method comprising administering a dose of 500 mg to 3000 mg of VIB4920 to a subject in need thereof, thereby treating the autoimmune disease or disorder.

[0010] The present specification further provides a method for reducing an index of RA disease activity in a patient undergoing RA treatment. The method includes administering VIB4920 to the patient, thereby decreasing an index of RA disease activity in the patient. The decreased index of RA disease activity may include one or more of DAS28-CRP, clinical disease activity index (CDAI), tender joint count, swollen joint count, patient global assessment, or physician global assessment. VIB4920 may be administered at a dose of about 500 mg to 3000 mg.

[0011] The present specification also provides a method for reducing RF autoantibodies in a patient undergoing treatment for RA, the method comprising the step of administering VIB4920 to the patient at a dose of about 500 mg to 3000 mg to reduce RF autoantibodies in the patient.

[0012] The present specification also provides a method for reducing a biomarker score in a patient undergoing RA treatment. The method includes administering about 500 mg to 3000 mg of VIB4920 to the patient, thereby reducing the biomarker score in the patient. In such a method, the biomarker score may be one or more of a plasma cell (PC) gene signature, a Vectra-DA score, or a serum C-reactive protein (CRP) level.

[0013] The present specification also provides a method for reducing a PC gene signature score of a patient in need thereof. The method includes administering VIB4920 to a patient in need thereof to reduce the patient's PC gene signature score. The patient in need thereof may be a patient undergoing treatment for systemic lupus erythematosus, rheumatoid arthritis, myositis, antiphospholipid syndrome, autoimmune hepatitis, Sjogren's disease, or other autoimmune or inflammatory conditions, as well as transplant surgery and graft-versus-host disease. The VIB4920 administered to the patient in need thereof may be at a dose of about 500 mg to 3000 mg.

[0014] The present specification further provides a method for reducing autoantibodies, or in the case of transplantation, alloantibodies, in a patient being treated for an autoimmune disorder. The method comprises the step of administering VIB4920 to a patient in need thereof to reduce autoantibodies or alloantibodies in the patient. In such methods, the patient is a patient being treated for an autoimmune disease characterized by the presence of autoantibodies, or the patient is a patient being treated to prevent transplant rejection. The patient is administered VIB4920 at a dose of about 500 mg to 3000 mg.

[0015] Also provided herein is a method for reducing inflammation in a patient. The method includes administering VIB4920 to a patient in need thereof to reduce inflammation in the patient. The patient may be a patient being treated for an inflammatory disease or disorder, or may be a patient being treated prophylactically for anticipated inflammation in response to an organ or tissue transplant. VIB4920 may be administered in a dose of about 500 mg to 3000 mg.

[0016] The present specification further provides a method of inducing immune tolerance to replacement therapy in a patient, the method comprising administering VIB4920 to a patient in need of replacement therapy, thereby reducing immune tolerance to the replacement therapy in the patient. VIB4920 may be administered at a dose of about 1000 mg to 3000 mg. [Brief description of the drawings]

[0017] [Fig. 1A-1G]

[0023] Figure 1 provides the biochemical properties of human CD40L-specific Tn3 clones, including the biochemical properties of VIB4920, a bivalent 342 clone fused to HSA. Figure 1A shows the ability of a series of human CD40L-specific Tn3 clones to inhibit CD40-CD40L interaction as measured by Proteon. Percent inhibition is shown across a range of Tn3 concentrations. The average of duplicate wells is shown. Figure 1B shows the ability of anti-CD40L Tn3 protein to inhibit CD40L-mediated signaling through NFkB. HEK293 cells expressing CD40R and an NFkB-luciferase reporter were stimulated with recombinant CD40L overnight in the presence of anti-CD40L Tn3 protein. Percent inhibition of luciferase activity is shown. Data represent the average of duplicate wells. Figure 1C shows the inhibition of CD86 upregulation by Tn3 constructs at various concentrations. Human PBMCs were stimulated with recombinant CD40L and preincubated with CD40L Tn3 protein, after which CD86 expression was assessed by flow cytometry. Means of duplicate wells are shown. In Figure 1D, the indicated Tn3 molecules were examined in an ELISA assay for their ability to inhibit the CD40-CD40L interaction. Data represent the mean of duplicate wells. In Figure 1E, data are provided from screening of clone 342 for binding to a panel of related TNF family members, including Fas, TNFα, TNFβ, and OX40L. Clone 342 was found to selectively bind CD40L. In Figure 1F, the proposed structure of VIB4920 is based on the crystallization of 342 Tn3 and the published crystal structure of HSA (1). In Figure 1G, a schematic of the CD40 / CD40L and 342 / CD40L structures arranged via a common CD40L molecule is shown. CD40L is shown in green, Tn3 in magenta, and the CD40 receptor in cyan. [Figures 2A-2D]Figure 2 provides structural features of human CD40L-specific Tn3 clone 342. Figure 2A shows a schematic of the trimeric 342 / CD40L structure. The extracellular domain of CD40L is shown in green and 342 in magenta. Figure 2B shows the interface between 342 and CD40L. Fragments of CD40L and 342 are shown as green and magenta tubes, respectively. Amino acids involved in hydrogen bonds are shown as sticks. Hydrogen bonds are shown as dashed black lines with associated distances (Å). Bonds with distances up to 3.5 Å are shown. Figures 2C and 2D illustrate the electrostatic surface potential of the surface interactions of CD40L (in Figure 2C) and 342 CD40L-specific Tn3 (in Figure 2D). To show the interface, the molecule has been rotated approximately 90 degrees and made semi-transparent to allow visualization of the amino acids involved in hydrogen bonds. Red indicates negatively charged surfaces and blue indicates positive charges. [Figure 3A-3G]Figure 3 shows how VIB4920 inhibits CD40 signaling and human B cell activation but does not induce platelet aggregation in ex vivo studies. Figure 3A shows the percentage of inhibition of NFkB luciferase signal by VIB4920 in modified HEK29 cells stimulated overnight with CD40L. Data represent the mean of duplicate wells. One of two independent experiments is shown. Figure 3B shows how VIB4920 and anti-CD40L mAb were able to inhibit the upregulation of CD86 in stimulated human PBMC. Human PBMC were stimulated with recombinant human megaCD40L for 24 hours and the percentage of CD19+ / CD86+ cells was measured by flow cytometry. Data represent the mean of duplicate wells. Figure 3C shows that human B cells were stimulated with IL-21 and megaCD40L in the presence of control or anti-CD40L (mAb or VIB4920 Tn3). B cell proliferation was quantified on day 3. The dotted line represents ATP levels in unstimulated cells. Data shown are the mean and SD of triplicate wells and are representative of two independent experiments. Figures 3D and 3E show the effect of anti-CD40L (mAb or VIB4920 Tn3) on human B cells left unstimulated (none) or stimulated with IL-21, anti-IgM and megaCD40L. The number of PCs was quantified on day 7. Figure 3D illustrates the effect of the indicated molecules on day 7 on the percentage of IgD-CD38hi PCs on day 7. Figure 3E shows the effect of the indicated molecules at the indicated concentrations on the number of PCs on day 7. Data shown are the mean and SD of triplicate wells and are representative of two independent experiments. ****=p<0.0001 by two-tailed unpaired Student's t-test. Figures 3F and 3G show the effect of anti-CD40L (mAb or VIB4920 Tn3) molecules on washed human platelets incubated with preformed immune complexes, and platelet aggregation or lack thereof was measured for 12-14 min. Figure 3F shows the aggregation rate. Shown here are platelets preincubated with anti-CD32a antibody for 5 min before adding immune complexes. Adenosine diphosphate (ADP) was used as a positive control for aggregation.Figure 3G provides the percentage of aggregation following incubation of platelets with immune complexes of VIB4920 (Tn3) or anti-CD40L mAb (5c8) at the indicated concentrations. Data are representative of two independent experiments. [Figure 4A-4B] Mouse surrogate CD40L-specific Tn3 responds to immunization and shows potent neutralizing activity in vivo. In both Figures 4A and 4B, mice were immunized with sheep red blood cells (SRBC) on day 0 and control or anti-CD40L Tn3 (M31-MSA) was administered daily for days 9-13. Figure 4A provides the percentage of germinal center B cells in spleen and lymph nodes quantified by flow cytometry on day 14. Points indicate individual animals and data are representative of two independent experiments. ****=p<0.0001 by two-tailed unpaired Student's t-test. Figure 4B provides the production of anti-sheep red blood cell IgG quantified from serum on day 14. Data show the mean and SEM of 4 animals per group (n=1 study). [Figure 5A-5B] Figure 5A is a study design for a Phase 1a clinical trial to evaluate the safety of VIB4920 in healthy volunteers. Figure 5A shows the study cohorts for the Phase 1a study. Figure 5B provides the dosing and immunization regimen for the Phase 1a study. [Figure 6A-6B] In a Phase 1a study in healthy volunteers, VIB4920 demonstrated a favorable PK profile. Figure 6A shows blood concentrations of VIB4920 measured by ELISA at the indicated time points. The dotted line represents the lower limit of sensitivity of the assay. Error bars represent standard deviation of the mean but were not calculated for groups of N=2 subjects. Figure 6B shows concentrations of soluble CD40L assessed by ELISA in all dose cohorts at the indicated time points. The dotted line represents the lower limit of detection of the assay. [Figure 7]VIB4920 inhibits anti-drug antibodies (ADA) at high doses in a Phase 1a study in healthy volunteers. Presence of ADA was measured by ELISA. Each subject within each cohort is represented by a separate line. Subjects with high ADA (>median titer 480) are shown by a magenta line, subjects with low ADA (<median titer 480) are shown by a dark blue line, and subjects with undetectable ADA are highlighted in light blue. [Figure 8A-8C] VIB4920 inhibits B cell proliferation and TDAR in a dose-dependent manner in healthy human volunteers. Healthy volunteers were immunized with KLH 14 days prior to treatment with placebo or VIB4920 and rechallenged 15 days after administration. Figure 8A provides anti-KLH IgG titers in healthy volunteers at different VIB4920 doses over multiple time points. Figure 8B provides anti-KLH IgM titers in healthy volunteers at different VIB4920 doses over multiple time points. IgG and IgM titers were measured by ELISA. Figure 8C is a dose-response model for inhibition of anti-KLH IgG at day 43. [Figure 9A-9C]VIB4920 inhibits B cell proliferation and plasma cell responses upon TDAR reduction in healthy human subjects. Figure 9A provides the detected frequency of circulating proliferating B cells (Ki67+ CD19+) quantified by flow cytometry at various time points in volunteers who received either placebo or high dose VIB4920 in the TDAR validation study. Figure 9B provides the detected frequency of circulating class-switched memory B cells (Ki67+ CD19+ IgD-CD27+) quantified by flow cytometry at various time points in volunteers who received either placebo or high dose VIB4920 in the TDAR validation study. Figure 9C provides the PC signature score in whole blood assessed by Taqman PCR. Mean and standard error expression values ​​for placebo and high dose VIB4920 groups are shown. *=P<0.05, **=P<0.01 compared to placebo by Mann-Whitney U test. [Figure 10] FIG. 1B is a Phase 1b study design for evaluating VIB4920 in patients with RA. Arrows indicate administration of VIB4920 or placebo. [Figure 11] Demographic and clinical characteristics of the cohort of RA patients in a phase 1b clinical trial of VIB4920. [Figure 12] Figure 1 shows an acceptable safety profile in RA patients with VIB4920. The most common TEAEs occurring in at least two subjects in a Phase 1b study in RA subjects are shown. [Figures 13A-13C]Figure 13 shows linear PK and dose-dependent reduction of ADA in a Phase 1b study of RA patients with VIB4920. Figure 13A provides the concentration of VIB4920 in the circulating blood as measured by ELISA at the indicated time points. The dotted line represents the lower limit of sensitivity of the assay. The mean and standard error of the mean are shown. Figure 13B provides the percentage of subjects with positive ADA titers as measured by ELISA for each dose administered at any time point during the study. Figure 13C provides ADA titers over time in subjects with detectable ADA as measured by ELISA. [Fig. 14A-14F] VIB4920 reduces disease index scores and autoantibodies in RA patients. Figure 14A shows the change from baseline in DAS28-CRP (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 14B shows the change from baseline in CDAI (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 14C shows the change from baseline in Patient Global Assessment (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 14D shows the change from baseline in Physician Global Assessment (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 14E shows the change from baseline in Vectra DA score (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. FIG. 14F shows measurements of percent reduction in RF antibody titers, as measured by ELISA, at the indicated time points for VIB4920 or placebo at the indicated doses, respectively. [Figure 15A-15B]VIB4920 reduces DAS28-CRP scores and RF autoantibodies in RA patients in a dose-dependent manner. Figure 15A shows the difference in DAS28-CRP scores between placebo and the indicated doses of VIB4920 at day 85. A linear dose-response is shown and identified as the best model for evaluating the relationship between VIB4920 dose and reduction in disease activity. Figure 15B shows the percent reduction in RF autoantibodies at the indicated doses of VIB4920 compared to placebo at day 85. The Emax model is shown and determined to be the best model for evaluating the relationship of VIB4920 dose to RF titer. [Figure 16] VIB4920 improves the DAS28 category in treated RA patients. DAS28 category at day 85 is shown. At day 85, 50% and 75% of treated RA patients in the 1000 mg and 1500 mg groups, respectively, had low disease activity or were in remission. [Figures 17A-17C] The effect of VIB4920 on tender / swollen joint counts and CRP in a Phase 1b study of RA subjects. Figure 17A shows the change from baseline in tender joint counts in RA subjects at the indicated doses and at the indicated time points. Figure 17B shows the change from baseline in swollen joint counts in RA subjects at the indicated doses and at the indicated time points. Figure 17C shows the percentage change in CRP levels to baseline in RA subjects at the indicated doses and at the indicated time points. Means and standard errors are shown, respectively. [Figure 18] Amino acid sequence of the VIB4920 molecule. [Figure 19A-19B] Amino acid sequence of the clone 342 CD40L-specific Tn3 molecule. [Figure 20] Amino acid sequence of the bivalent clone 342 CD40L-specific Tn3 molecule. [Figure 21A-21B] Amino acid sequence of the clone 309 CD40L-specific Tn3 molecule. [Fig. 22A-22F]VIB4920 reduces disease index scores and autoantibodies in RA patients during both the 12-week VIB4920 administration period and the 12-week observation period after the last VIB4920 dose. Figure 22A shows the change from baseline in DAS28-CRP (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 22B shows the change from baseline in CDAI (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 22C shows the change from baseline in Patient Global Assessment (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 22D shows the change from baseline in Physician Global Assessment (mean and standard error shown) assessed at the indicated time points for a particular dose of VIB4920 or placebo. Figure 22E shows the change from baseline in Vectra DA scores (mean and standard error shown) assessed at the indicated time points for specific doses of VIB4920 or placebo. Figure 22F shows measurements of the percent reduction in RF antibody titers measured by ELISA at the indicated time points for the indicated doses of VIB4920 or placebo, respectively. [Figures 23A-23C] VIB4920 affects tender / swollen joint counts and CRP in RA patients. The effect of VIB4920 can be detected in a Phase 1b clinical trial in RA patients, both during the administration phase and during the 12-week observation period after administration. Figure 23A shows the change from baseline in tender joint counts in RA subjects at the indicated doses and at the indicated time points. Figure 23B shows the change from baseline in swollen joint counts in RA subjects at the indicated doses and at the indicated time points. Figure 23C shows the change in the ratio of CRP levels to baseline in RA subjects at the indicated doses and at the indicated time points. Mean and standard error are shown, respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Described herein is VIB4920 and its utility in methods for suppressing B cell mediated immune responses, for treating an autoimmune disease or disorder, for reducing inflammation, for reducing autoantibodies in a patient, for reducing an indicator of RA disease activity in a patient, for reducing RF autoantibodies in a patient, for reducing a gene signature score of plasma cells in a patient, and for inducing immune tolerance to replacement therapy in a patient.

[0019] When VIB4920 is used to treat an autoimmune disease or disorder, VIB4920 is used to treat an autoimmune disease or disorder, including, but not limited to, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, Sjogren's syndrome, psoriasis, atherosclerosis, diabetic retinopathy and other retinopathies, retrolental fibroplasia, age-related macular degeneration, neovascular glaucoma, hemangiomas, thyroid hyperplasia (including Graves' disease), corneal and other tissue transplants, and chronic inflammation, sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, sepsis, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, arthritis (e.g., psoriatic arthritis), anaphylactic shock, organ ischemia, reperfusion injury, spinal cord injury and allograft rejection, autoimmune thrombocytopenia, Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue and immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia cystic fibrosis, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, graft-versus-host disease, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, juvenile arthritis, lichen planus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, IgG4-mediated disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndrome, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis In some embodiments, it may be used to treat chronic arthritis, Raynaud's phenomenon, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, Takayasu's arteritis, other vasculitis such as temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, ANCA-associated vasculitis, dermatitis herpetiformis vasculitis, vitiligo, solid organ transplant rejection, graft-versus-host disease, desensitization of panel-reactive antibodies in kidney transplant recipients, islet cell transplantation and allogeneic hematopoietic stem cell transplantation, focal segmental glomerulosclerosis (FSGS), glomerulonephritis.

[0020] VIB4920 may more particularly be used to treat RA, systemic lupus erythematosus (SLE), myositis, antiphospholipid syndrome, autoimmune hepatitis, focal segmental glomerulosclerosis (FSGS), lupus nephritis, inflammatory myopathy, idiopathic thrombocytopenic purpura (ITP), systemic sclerosis, vasculitis, cutaneous lupus, autoimmune hemolytic anemia, myasthenia gravis, IgG4-related disease, or Sjogren's syndrome. Additionally, VIB4920 may be used to treat graft-versus-host disease and / or reduce or prevent rejection of organ or tissue transplants.

[0021] Treating an autoimmune disease or disorder may be in the form of suppressing B-cell or T-cell mediated immune responses, which may be by reducing class-switched antibodies, reducing circulating B-cell subsets, reducing plasma activity, or reducing plasma cells and plasma cell gene signatures. Treating an autoimmune disease or disorder may be by reducing inflammatory markers. The inflammatory markers may be one or more of autoantibody levels, plasma cells (PC) or PC gene signatures (signatures characterized by the expression of genes IGHA1, IGJ, IGKC, IGKV4-1 and TNFRSF17), circulating B-cell subsets, and class-switched antibodies. Treating an autoimmune disease or disorder may be by reducing clinical signs and symptoms as measured by a patient or physician's global assessment. Clinical signs and symptoms may include one or more of arthritis, pain, fatigue, fever, malaise, rash, weakness, or signs of organ failure such as proteinuria or loss of kidney function.

[0022] When the method is to reduce autoantibodies in a patient being treated for an autoimmune disorder, the autoantibody may be, for example, an antinuclear antibody in a patient being treated for SLE, Sjogren's syndrome, inflammatory myopathy, or systemic sclerosis. The antinuclear antibody may be one or more of anti-SSA / Ro or anti-SSB-La autoantibodies (SLE or Sjogren's syndrome), anti-dsDNA antibodies (SLE), anti-Smith antibodies (SLE), anti-topoisomerase antibodies (systemic sclerosis), or anti-histone antibodies (SLE). When the method is to reduce autoantibodies in a patient being treated for an autoimmune disorder, the autoantibody may be, for example, a liver-kidney microsomal type 1 antibody in a patient being treated for autoimmune hepatitis. When the method is to reduce autoantibodies in a patient being treated for an autoimmune disorder, the autoantibody may be, for example, an anti-nicotinic acetylcholine receptor antibody or an anti-muscle specific kinase antibody in a patient being treated for myasthenia gravis. When the method is to reduce antibodies in a patient being treated for transplant surgery, the antibody may be an alloantibody.

[0023] Reducing autoantibodies in a patient being treated for an autoimmune disorder may mean reducing the proportion of autoantibodies to a level that is at least 20% lower than before administration of VIB4920. This may mean reducing the proportion of autoantibodies to a level that is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80% compared to the level of autoantibodies before treatment with VIB4920. The reduction in autoantibodies may be achieved within 1 to 3 months of initiating administration of VIB4920.

[0024] When the autoimmune disease or disorder is RA, treating rheumatoid arthritis may be reducing one or more of RF autoantibodies, anti-citrullinated peptide antibodies, Vectra DA biomarker score (Vectra DA biomarker score is a composite score of expression levels of interleukin-6, tumor necrosis factor receptor type I, vascular cell adhesion molecule 1, epidermal growth factor, vascular endothelial growth factor A, YKL-40, matrix metalloproteinase 1, MMP-3, CRP, serum amyloid A, leptin, and resistin), plasma cell (PC) signature, serum reactive C-protein (CRP), DAS28-CRP, or clinical disease activity index (CDAI), or reducing tender joint count, swollen joint severity, swollen joint count, or swollen joint severity. When the autoimmune disease or disorder is RA, treating may be achieving ACR20, ACR50, or ACR70.

[0025] Treatment of an autoimmune disease or disorder may be characterized by a reduction in clinical symptoms of the disease or disorder by at least 20%, or a reduction in inflammation, or a reduction in a biomarker of the disease or disorder, compared to levels prior to treatment with VIB4920. The reduction in any of these symptoms, inflammation, or biomarkers may be a reduction in the symptoms, inflammation, or biomarkers by at least 50%, compared to levels prior to beginning treatment with VIB4920. The reduction may be such that the autoimmune disease or disorder is characterized by being in remission.

[0026] Further, where the autoimmune disease or disorder is rheumatoid arthritis, treating the autoimmune disease or disorder may be reducing RF autoantibodies in the patient to a level of about at least 20%, at least 30%, at least 40%, at least 45%, at least 50%, at least 60%, at least 75%, or at least 80% compared to the RF autoantibody level prior to treatment with VIB4920. Where the autoimmune disease or disorder is rheumatoid arthritis, treating the autoimmune disease or disorder may be reducing DAS28-CRP, where reducing DAS28-CRP may be such that there is an adjusted mean difference of at least -1.2, or at least -1.5, or at least -2.0, or at least -2.2. Additionally, where the autoimmune disease or disorder is rheumatoid arthritis, treating the autoimmune disease or disorder may be reducing the Vectra DA biomarker score, which may be an adjusted mean difference of at least -10.3, or at least -10.5, or at least -10.8.

[0027] When VIB4920 is used in a method for reducing inflammation, the inflammation may be the result of an inflammatory disease or disorder, or may be due to injury, such as from an organ or tissue transplant procedure, or may be in anticipation of such injury. When VIB4920 is used in a method for reducing inflammation in an inflammatory disease or disorder, the inflammatory disease or disorder may be inflammatory myopathy, or lupus nephritis, cutaneous lupus, RA, SLE, ITP, myositis, Sjogren's syndrome, vasculitis, systemic sclerosis, autoimmune hemolytic anemia, myasthenia gravis, or focal segmental glomerulosclerosis. When VIB4920 is used in a method for reducing inflammation, the inflammation may be due to injury, such as from an organ or tissue transplant procedure, or may be in anticipation of such injury.

[0028] When VIB4920 is used in a method for inducing immune tolerance to a replacement therapy in a patient, VIB4920 can induce immune tolerance by decreasing the patient's production of neutralizing antibodies to the replacement therapy. If the patient is naive to the replacement therapy, or has otherwise not yet produced neutralizing antibodies to the replacement therapy, inducing immune tolerance can first prevent the patient from producing neutralizing antibodies to the replacement therapy. However, if the patient produces neutralizing antibodies to the replacement therapy, VIB4920 can induce immune tolerance by decreasing the level of neutralizing antibodies to the replacement therapy produced by the patient. The level of neutralizing antibodies produced by the patient to the replacement therapy can be reduced by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or to an undetectable level. A percent reduction in the level of neutralizing antibody production in response to replacement therapy in a patient may be compared to or determined by comparing a first level of neutralizing antibody produced in response to replacement therapy prior to administration of a first dose of VIB4920 to a second level of neutralizing antibody produced in response to replacement therapy after administration of the first or second or third or fourth or fifth dose of VIB4920. Alternatively, a percent reduction in the level of neutralizing antibody production in response to replacement therapy in a patient may be compared to or determined by comparing a peak level of neutralizing antibody produced in response to replacement therapy prior to administration of a first dose of VIB4920 to a peak level of neutralizing antibody produced in response to replacement therapy after administration of the first or second or third or fourth or fifth dose of VIB4920.

[0029] Alternatively, or in addition, inducing immune tolerance to replacement therapy in a patient may be reducing the T cell response to replacement therapy. If the patient is naive to replacement therapy, or has received replacement therapy but has not yet developed a T cell immune response to replacement therapy, VIB4920 can reduce the patient's T cell response by preventing the formation of an initial T cell response to replacement therapy. However, if the patient has an existing T cell response to replacement therapy, VIB4920 can induce immune tolerance by reducing the existing T cell response to replacement therapy. The T cell response to replacement therapy can be reduced by at least 50%, at least 55%, at least 60%, at least 65%, at least 70, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or to an undetectable level. The percent reduction in the patient's T cell response to replacement therapy may be compared to or determined by a first level of T cell response to replacement therapy before administration of a first dose of VIB4920 compared to a second level of T cell response to replacement therapy after administration of a first or second or third or fourth or fifth dose of VIB4920. Alternatively, the percent reduction in the patient's T cell response to replacement therapy may be compared to or determined by a peak level of T cell response to replacement therapy before administration of a first dose of VIB4920 compared to a peak level of T cell response to replacement therapy after administration of a first or second or third or fourth or fifth dose of VIB4920. The reduction in the T cell response may be characterized by a reduction in proliferation and / or stimulation of CD4+ T cells stimulated by the replacement therapy. The reduction in the T cell response may also be characterized by a reduction in CD4-dependent CD8+ T cell response to replacement therapy.

[0030] The replacement therapy by which immune tolerance is induced may be a peptide or protein replacement therapy. When the replacement therapy is a peptide or protein therapy, it may be factor VIII or factor IX therapy and may be administered to treat patients suffering from hemophilia. When the replacement therapy is a peptide or protein therapy, it may be enzyme replacement therapy (ERT). When the replacement therapy is an ERT, it may be agalsidase alpha or agalsidase beta, which may replace α-galactosidase A and may treat patients suffering from Fabry disease. When the replacement therapy is an ERT, it may be ialonidase, which may replace α-L-iduronidase and may treat patients suffering from mucopolysaccharidosis (MPS) type 1 (also known as Hurler syndrome, Hurler-Scheie syndrome or Scheie syndrome depending on its severity). When the replacement therapy is ERT, the replacement therapy may be alglucosidase, which may replace α-glucosidase, and may treat patients with Pompe disease. When the replacement therapy is ERT, the replacement therapy may be idursulfase, which may replace iduronate-2-sulfatase, and may treat patients with MPS II. When the replacement therapy is ERT, the replacement therapy may be imiglucerase or velaglucerase alpha or taliglucerase alpha, which may replace β-glucocerebrosidase, and may treat patients with Gaucher disease. When the replacement therapy is ERT, the replacement therapy may be Naglazyme arylsulfatase B, which may replace N-acetylgalactosamine-4-sulfatase, and may treat patients with MPS VI. Where the peptide or protein replacement therapy is a peptide or protein, immune tolerance induction can reduce the production of neutralizing antibodies against the peptide or protein and / or reduce the T cell response by the patient against the peptide or protein.

[0031] Furthermore, the replacement therapy in which immune tolerance is induced may be a viral vector comprising a nucleic acid encoding a therapeutic peptide or protein. When the replacement therapy is a viral vector comprising a nucleic acid encoding a therapeutic peptide or protein, the viral vector may be an adenovirus vector, an adeno-associated virus vector, a retrovirus vector, a poxvirus, an alphavirus, a herpes simplex virus vector, or any other viral vector capable of delivering a nucleic acid encoding a therapeutic peptide or protein to cells of a patient. The viral vector may be modified, for example, by pseudotyping and / or to delete its wild-type gene and / or to comprise a nucleic acid encoding a therapeutic peptide or protein.

[0032] The therapeutic peptide or protein encoded by the nucleic acid of the viral vector may be a therapeutic peptide or protein of factor VIII or factor IX, or may be an ERT such as agalsidase alfa, agalsidase beta, idursulfase, ialonidase, alglucosidase alfa, imiglucerase, velaglucerase alfa, taliglucerase alfa, or naglazyme arylsulfatase B.

[0033] Furthermore, when the replacement therapy is a viral vector comprising a nucleic acid encoding a therapeutic peptide or protein, VIB4920 can induce immune tolerance by reducing the immune response to the viral vector, or by reducing the immune response to the therapeutic peptide or protein encoded by the viral vector, or both. VIB4920 can induce immune tolerance to the viral vector by reducing neutralizing antibody and / or T cell responses to the viral vector, either the vector itself, or cells infected with the viral vector. Additionally or alternatively, VIB4920 can induce immune tolerance to a replacement therapy consisting of a viral vector by reducing neutralizing antibody or T cell responses to the therapeutic peptide or protein encoded by the nucleic acid of the viral vector.

[0034] VIB4920 used in the various methods may comprise an amino acid sequence as shown in Figure 18. VIB4920 may have an amino acid sequence as shown in Figure 18 or may have one or more amino acid residue modifications relative to the amino acid sequence as shown in Figure 18. Where VIB4920 has an amino acid sequence modification relative to the amino acid sequence as shown in Figure 18, the modification may be to one of the linkers. VIB4920 contains a Gly15 linker separating the two CD40L-specific monomers and a Gly10 linker separating the CD40L-specific monomer from the HSA sequence. Either or both of these linkers may be altered, and the amino acid sequence (G m X) nwhere X is serine (S), alanine (A), glycine (G), leucine (L), isoleucine (I) or valine (V), m and n are integer values, m is 1, 2, 3 or 4, and n is 1, 2, 3, 4, 5, 6 or 7. For example, one or both linkers may be altered to have an amino acid sequence that includes one of GGGGSGGGGS, GGGGSGGGGSGGGGGS, GGGGGGGGGG or GGGGGGGGGGGGGG. Where VIB4920 has an amino acid sequence related to the amino acid sequence shown in Figure 18, this may be due to alteration or modification of the amino acid sequence of HSA fused to two CD40L-specific monomers. The HSA fused to two CD40L-specific monomers may be altered relative to the HSA fused to two CD40L-specific Tn3 monomers at positions selected from the group consisting of 407, 415, 463, 500, 506, 508, 509, 511, 512, 515, 516, 521, 523, 524, 526, 535, 550, 557, 573, 574, and 580, numbered relative to positions in full-length mature HSA, except for at least one amino acid substitution, where the at least one amino acid substitution does not include the substitution of lysine (K) to glutamic acid (E) at position 573. Where VIB4920 has an amino acid sequence modification relative to the amino acid sequence shown in Figure 18, the modification may be to the amino acid sequence of one or both CD40L-specific Tn3 monomers, for example such that one or both CD40L-specific Tn3 monomers have the amino acid sequence as shown in Figure 19A, so long as the modification does not adversely affect the efficacy of VIB4920 in vivo.

[0035] The dose of VIB4920 administered in this method may be about 500mg to about 3000mg. The dose may be about 750mg to about 3000mg, or about 1000mg to about 3000mg, or about 1500mg to about 3000mg, or about 500mg to about 2000mg, or about 750mg to about 2000mg, or about 1000mg to about 2000mg, or about 1000mg to about 2500mg, or about 1000mg to about 1500mg. The dose may be 500mg, 750mg, 900mg, 1000mg, 1250mg, 1500mg, 1750mg, 2000mg, 2250mg, 2500mg, or 3000mg.

[0036] The dose of VIB4920 may be administered about every other week or twice a month. The dose of VIB4920 may also be administered about every week or about once a month. The dose of VIB4920 may also be administered every 7 days, every 10 days, every 14 days, every 15 days, every 16 days, every 14-10 days, every 14-16 days, or every 30 days. The dose of VIB4920 may also be administered by intravenous or subcutaneous injection.

[0037] If the dose of VIB4920 administered is one of 1000 mg, 1500 mg, or about 1000 mg to about 1500 mg, the dose may be administered every other week or twice a month. If the dose of VIB4920 is 3000 mg, the dose of VIB4920 may be administered once a month. If the dose of VIB4920 is 500 mg or 750 mg, the dose of VIB4920 may be administered once every other week or alternatively twice a month. Any of these doses may be administered intravenously.

[0038] The dose and dosing regimen of VIB4920 may be such that any therapeutic effect achieved by administering VIB4920 to treat any autoimmune / inflammatory disease or disorder, such as reduction in autoantibodies, reduction in Vectra DA score, reduction in plasma cell signature, reduction in CRP, reduction in DAS28-CRP, reduction in swollen joint count, reduction in tender joint count, reduction in CDAI, improved patient global assessment, improved physician global assessment, achievement of ACR20, achievement of ACR50, or achievement of ACR70, can be considered "long-term sustained." A "long-lasting" effect of VIB4920 in treating an autoimmune / inflammatory disease or disorder is one in which the therapeutic effect achieved by VIB4920 is maintained for at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks, at least 12 weeks, at least 16 weeks, at least 20 weeks, or at least 24 weeks after the last dose of a course of VIB4920 is administered (even though VIB4920 is no longer being administered). A course of VIB4920 may involve administration of doses of 500 mg to 3000 mg (e.g., 500 mg, 750 mg, 1000 mg, 1250 mg, 1500 mg, 1750 mg, 2000 mg, 2250 mg, 2500 mg, 2750 mg, or 3000 mg) of VIB4920 at dosing intervals of once every 7 to 31 days (e.g., every 7 days, every 10 days, every 14 days, every 15 days, every 16 days, every 14 to 10 days, every 14 to 16 days, or every 30 days) over a period of about 8 to 24 weeks (e.g., 8 weeks, or 10 weeks, or 12 weeks, or 14 weeks, or 16 weeks, or 18 weeks, or 20 weeks, or 22 weeks, or 24 weeks, or 2 months, or 4 months, or 6 months).

[0039] The present disclosure encompasses the following embodiments. [Section 1] 1. A method for suppressing a B cell mediated immune response in a subject, comprising: administering to a subject in need thereof a dose of 500 mg to 3000 mg of VIB4920; and and suppressing the B cell mediated immune response. [Section 2] Item 1. The method according to item 1, wherein the dose is 1000 mg to 1500 mg of VIB4920. [Section 3] 3. The method of claim 2, wherein the dose is 1000 mg of VIB4920. [Section 4] 3. The method of claim 2, wherein the dose is 1500 mg of VIB4920. [Section 5] 5. The method of any one of paragraphs 1 to 4, wherein the dose is administered every 14 days or twice a month. [Section 6] 6. The method according to any one of items 1 to 5, wherein the dose is administered intravenously. [Section 7] Item 7. The method according to any one of Items 1 to 6, wherein the suppression of the B cell immune response is a decrease in antibody class switching. [Section 8] Item 7. The method according to any one of Items 1 to 6, wherein the suppression of the B cell-mediated immune response comprises reducing circulating B cells. [Section 9] Item 7. The method according to any one of Items 1 to 6, wherein the suppression of the B cell-mediated immune response comprises reducing the activity of plasma cells. [Section 10] 10. The method of any one of clauses 9, wherein said reduction in plasma cell activity is a reduction in plasma cell signature. [Section 11] Item 11. The method of item 10, wherein the decrease in plasma cell signature is a decrease in expression of genes IGHA1, IGJ, IGKC, IGKV4-1, and TNFRSF17. [Section 12] 1. A method for treating an autoimmune disease or disorder, comprising: administering to a patient in need thereof a dose of 500 mg to 3000 mg of VIB4920; and treating said autoimmune disease or disorder. [Section 13] Item 13. The method according to item 12, wherein the dose is 1000 mg to 1500 mg of VIB4920. [Section 14] 14. The method of claim 13, wherein the dose is 1000 mg of VIB4920. [Section 15] 15. The method of claim 14, wherein the dose is 1500 mg of VIB4920. [Section 16] 16. The method of any one of items 12 to 15, wherein the dose is administered every 14 days or twice a month. [Section 17] Item 17. The method according to any one of items 12 to 16, wherein the dose is administered intravenously. [Section 18] Item 18. The method according to any one of Items 12 to 17, wherein the treating the autoimmune disease or injury is a reduction in an inflammatory marker. [Section 19] The method of claim 18, wherein the inflammatory markers include one or more of autoantibody levels, plasma cell (PC) signature, circulating B cells, and antibody class switching. [Section 20] 20. The method of claim 18, wherein said treating is reducing a clinical symptom. [Section 21] Item 13. The method of item 12, wherein the autoimmune disease or disorder is rheumatoid arthritis. [Section 22] The method of claim 21, wherein the treating is to reduce one or more of rheumatoid factor (RF) autoantibodies, Vectra DA biomarker score, plasma cell (PC) signature, seroreactive C-protein (CRP), DAS28-CRP, swollen joint count, tender joint count, or clinical disease activity index (CDAI). [Section 23] 23. The method of claim 22, wherein said treating is reducing rheumatoid factor autoantibodies. [Section 24] 24. The method of claim 23, wherein the reduction in RF autoantibodies is by at least 50% within 85 days after initiation of treatment. [Section 25] 23. The method of claim 22, wherein the treating is reducing DAS28-CRP. [Section 26] 26. The method of claim 25, wherein the reduction in DAS28-CRP is an adjusted mean difference of at least -1.2. [Section 27] 26. The method of clause 25, wherein said decrease in DAS28-CRP is detectable after administration of a single dose of VIB4920. [Section 28] The method of claim 22, wherein the treating is decreasing the Vectra DA biomarker score. [Section 29] 29. The method of claim 28, wherein the reduction in the Vectra DA biomarker score is an adjusted mean difference of at least -10.3. [Section 30] 13. The method of claim 12, wherein the autoimmune disease or disorder is one of systemic sclerosis, myositis, antiphospholipid syndrome, autoimmune hepatitis, lupus nephritis, idiopathic thrombocytopenic purpura, vasculitis, cutaneous lupus, autoimmune hemolytic anemia, Sjogren's disease, IgG4-related disease, or systemic lupus erythematosus. [Section 31] 31. The method of claim 30, wherein said treating is reducing a clinical symptom of said autoimmune disease or disorder. [Section 32] 31. The method of claim 30, wherein said treating is reducing a PC signature. [Section 33] 33. The method of claim 32, wherein the decrease in PC signature is a decrease in expression of genes IGHA1, IGJ, IGKC, IGKV4-1, and TNFRSF17. [Section 34] 31. The method of claim 30, wherein said treating is reducing one or more biomarkers of said autoimmune disease or disorder. [Section 35] 1. A method for reducing an indicator of rheumatoid arthritis (RA) disease activity in a patient being treated for RA, comprising: administering to said patient VIB4920, The indicators of RA disease activity include one or more of DAS28-CRP, Clinical Disease Activity Index (CDAI), Patient Global Assessment, or Physician Global Assessment; said VIB4920 being administered at a dose of about 500 mg to 3000 mg; and reducing said indicator of RA disease activity in said patient. [Section 36] Item 36. The method of item 35, wherein the VIB4920 is administered at a dose of about 1000 mg to 2000 mg. [Section 37] Item 37. The method of item 36, wherein the VIB4920 is administered at a dose of about 1000 mg to 1500 mg. [Section 38] 38. The method of claim 37, wherein the VIB4920 is administered at a dose of about 1000 mg. [Section 39] 38. The method of claim 37, wherein the VIB4920 is administered at a dose of about 1500 mg. [Section 40] 40. The method of any one of items 35 to 39, wherein the VIB4920 is administered every 14 days or twice a month. [Section 41] Item 41. The method of any one of items 35 to 40, wherein the VIB4920 is administered intravenously. [Section 42] Item 42. The method according to any one of Items 35 to 41, wherein the index is DAS28-CRP, and the decreasing means that the adjusted mean change is at least -1.2. [Section 43] 43. The method of claim 42, wherein the reducing is an adjusted mean change of at least -2.2. [Section 44] Item 42. The method according to any one of items 35 to 41, wherein the indicator is DAS28-CRP and the decrease is observed after the first dose of VIB4920. [Section 45] 1. A method for reducing rheumatoid factor (RF) autoantibodies in a patient undergoing treatment for rheumatoid arthritis, comprising: administering to the patient a dose of about 500 mg to 3000 mg of VIB4920; and reducing RF autoantibodies in said patient. [Section 46] Item 46. The method according to item 45, wherein the dose is about 1000 mg to about 2000 mg. [Section 47] Item 47. The method according to item 46, wherein the dose is about 1000 mg to about 1500 mg. [Section 48] 48. The method of claim 47, wherein the dose is about 1000 mg. [Section 49] 49. The method of claim 48, wherein the dose is about 1500 mg. [Section 50] 50. The method of any one of clauses 45 to 49, wherein the dose is administered every 14 days or twice a month. [Section 51] 51. The method of any one of items 45 to 50, wherein the dose is administered intravenously. [Section 52] Item 52. The method of any one of items 45 to 51, wherein the RF autoantibodies are reduced by at least 40%. [Section 53] Item 52. The method according to any one of items 46 to 51, wherein the RF autoantibodies are reduced by at least 50%. [Section 54] Item 54. The method according to any one of Items 46 to 53, wherein the RF autoantibody is reduced within 85 days after the start of treatment. [Section 55] 1. A method for reducing a biomarker score in a patient being treated for rheumatoid arthritis, comprising: administering to the patient about 500 mg to 3000 mg of VIB4920, the biomarker score being one or more of a plasma cell (PC) gene signature, a Vectra-DA score, or a serum C-reactive protein level (CRP); and decreasing said biomarker score in said patient. [Section 56] Item 56. The method according to item 55, wherein the dose is about 1000 mg to about 2000 mg. [Section 57] Item 57. The method according to item 56, wherein the dose is about 1000 mg to about 1500 mg. [Section 58] 58. The method of claim 57, wherein the dose is about 1000 mg. [Section 59] 59. The method of claim 58, wherein the dose is about 1500 mg. [Section 60] 60. The method of any one of clauses 55 to 59, wherein the dose is administered every 14 days or twice a month. [Section 61] Item 61. The method of any one of items 55 to 60, wherein the dose is administered intravenously. [Section 62] Item 62. The method of any one of items 55 to 61, wherein the biomarker score is Vectra DA and the decreasing is an adjusted mean difference of at least -10.3. [Section 63] Item 62. The method according to any one of Items 57 to 61, wherein the biomarker score is serum CRP. [Section 64] 1. A method for reducing a plasma cell (PC) gene signature score in a patient in need thereof, comprising: administering VIB4920 to a patient in need thereof; the patient is being treated for systemic lupus erythematosus, rheumatoid arthritis, myositis, antiphospholipid syndrome, autoimmune hepatitis, or Sjogren's disease; said VIB4920 being administered at a dose of about 500 mg to 3000 mg; and decreasing said patient's PC gene signature score. [Section 65] Item 65. The method according to item 64, wherein the dose is about 1000 mg to about 2000 mg. [Section 66] Item 66. The method according to item 65, wherein the dose is about 1000 mg to about 1500 mg. [Section 67] 67. The method of claim 66, wherein the dose is about 1000 mg. [Section 68] 68. The method of claim 67, wherein the dose is about 1500 mg. [Section 69] 69. The method of any one of claims 64 to 68, wherein the dose is administered every 14 days or twice a month. [Section 70] 70. The method of any one of claims 64 to 69, wherein the dose is administered intravenously. [Section 71] 1. A method for reducing autoantibodies in a patient undergoing treatment for an autoimmune disorder, comprising: administering VIB4920 to a patient in need thereof; the patient is being treated for an autoimmune disease characterized by the presence of autoantibodies; said VIB4920 being administered at a dose of about 500 mg to 3000 mg; and reducing said autoantibodies in said patient. [Section 72] Item 72. The method according to item 71, wherein the dose is about 1000 mg to about 2000 mg. [Section 73] Item 73. The method according to item 72, wherein the dose is about 1000 mg to about 1500 mg. [Section 74] 74. The method of claim 73, wherein the dose is about 1000 mg. [Section 75] 74. The method of claim 73, wherein the dose is about 1500 mg. [Section 76] 76. The method of any one of clauses 71 to 75, wherein the dose is administered every 14 days or twice a month. [Section 77] 77. The method of any one of claims 71 to 76, wherein the dose is administered intravenously. [Section 78] Item 78. The method according to any one of Items 71 to 77, wherein the autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis, myositis, antiphospholipid syndrome, autoimmune hepatitis, or Sjogren's disease. [Section 79] 1. A method for reducing inflammation in a patient, comprising: administering VIB4920 to a patient in need thereof; the patient is being treated for an inflammatory disease or disorder or is being treated prophylactically for anticipated inflammation in response to an organ or tissue transplant; said VIB4920 being administered at a dose of about 1000 mg to 3000 mg; and reducing inflammation in said patient. [Section 80] Item 80. The method according to item 79, wherein the dose is about 1000 mg to about 2000 mg. [Section 81] Item 81. The method according to item 80, wherein the dose is about 1000 mg to about 1500 mg. [Section 82] 80. The method of claim 79, wherein the dose is about 1000 mg. [Section 83] 80. The method of claim 79, wherein the dose is about 1500 mg. [Section 84] 80. The method of claim 79, wherein the dose is about 3000 mg. [Section 85] 85. The method of any one of clauses 79 to 84, wherein the dose is administered every 14 days or twice a month. [Section 86] 86. The method of any one of clauses 79 to 85, wherein the dose is administered intravenously. [Section 87] 85. The method of claim 84, wherein said dose is administered once per month. [Section 88] 88. The method according to any one of items 79 to 87, wherein the patient is concomitantly treated or prophylactically treated to prevent rejection of an organ or tissue transplant. [Section 89] Item 88. The method according to any one of Items 79 to 87, wherein the inflammatory disease or disorder is inflammatory myopathy, or lupus nephritis, cutaneous lupus, RA, SLE, ITP, myositis, Sjogren's syndrome, vasculitis, systemic sclerosis, autoimmune hemolytic anemia, myasthenia gravis, or focal segmental glomerulosclerosis. [Section 90] 22. The method of claim 21, wherein the treating is to achieve ACR20, ACR50, or ACR70. [Section 91] Item 12. The method according to any one of items 1 to 11, wherein the suppression of the B cell-mediated immune response lasts for a long period of time. [Section 92] Item 13. The method of any one of items 12 to 34 or 90, wherein said treatment of said autoimmune disease or injury is long-lasting. [Section 93] Item 45. The method according to any one of items 35 to 44, wherein the reduction in the index of RA disease activity in the patient is sustained over time. [Section 94] 55. The method of any one of items 45 to 54, wherein the reduction in RF autoantibodies in the patient is sustained over time. [Section 95] Item 64. The method of any one of items 55 to 63, wherein the decrease in the biomarker in the patient is sustained over time. [Section 96] 71. The method of any one of paragraphs 64 to 70, wherein the decrease in the patient's PC gene signature score is sustained over time. [Section 97] 79. The method of any one of paragraphs 71 to 78, wherein the reduction in the autoantibodies in the patient is sustained over time. [Section 98] 90. The method of any one of paragraphs 79 to 89, wherein the reduction in inflammation in the patient is sustained over time. [Section 99] 1. A method of inducing immune tolerance to replacement therapy in a patient, comprising: administering VIB4920 to a patient in need of replacement therapy, said VIB4920 being administered at a dose of about 1000 mg to 3000 mg; and reducing immune tolerance to said replacement therapy in said patient. [Section 100] 100. The method of claim 99, wherein the VIB4920 is administered at a dose of about 1500 mg to 3000 mg. [Section 101] Item 101. The method of item 100, wherein the VIB4920 is administered at a dose of about 2500 mg to 3000 mg. [Section 102] 102. The method of claim 101, wherein the VIB4920 is administered at a dose of about 3000 mg. [Section 103] 103. The method of any one of clauses 99-102, wherein the dose is administered approximately once every 2-4 weeks. [Section 104] 104. The method of claim 103, wherein said dose is administered about once every four weeks. [Section 105] 103. The method of claim 102, wherein said dose is administered once per month. [Section 106] 106. The method of any one of paragraphs 99, 102 or 105, wherein the replacement therapy is a protein or peptide. [Section 107] 107. The method of paragraph 106, wherein said inducing immune tolerance comprises reducing the production of neutralizing antibodies against said protein or peptide by said patient. [Section 108] 108. The method of claim 107, wherein the protein is Factor VIII and the patient is a hemophilia patient. [Section 109] 108. The method of claim 107, wherein the protein is Factor IX and the patient is a hemophilia patient. [Section 110] 109. The method of claim 108, wherein said inducing immune tolerance is reducing neutralizing anti-Factor VIII antibodies in said patient. [Section 111] 107. The method of claim 106, wherein the protein or peptide is an enzyme. [Section 112] 112. The method of claim 111, wherein the enzyme is agalsidase alpha or agalsidase beta and the patient is a Fabry disease patient. [Section 113] 112. The method of claim 111, wherein the enzyme is idursulfase and the patient is a mucopolysaccharidosis II patient or a Hunter syndrome patient. [Section 114] 112. The method of claim 111, wherein the enzyme is arylonidase and the patient is a mucopolysaccharidosis I patient. [Section 115] 112. The method of claim 111, wherein the enzyme is alglucosidase alfa and the patient is a Pompe disease patient. [Section 116] 107. The method of any one of paragraphs 99, 102 or 105, wherein the replacement therapy is a viral vector comprising a nucleic acid encoding a therapeutic peptide or protein. [Section 117] 117. The method of claim 116, wherein said inducing immune tolerance to said replacement therapy comprises reducing an immune response in said patient to said viral vector, reducing neutralizing antibodies to said therapeutic protein, or both. [Section 118] 118. The method of claim 117, wherein the viral vector is an adeno-associated virus (AAV). [Section 119] The method of claim 118, wherein said inducing immune tolerance comprises reducing an immune response to said AAV. [Section 120] 120. The method of claim 119, wherein the reducing the immune response to the AAV is reducing a T cell response to the AAV or reducing antibodies to the AAV. [Section 121] The method of claim 120, wherein said reducing T cell response is reducing T cell response to AAV capsid protein. [Section 122] 118. The method of claim 117, wherein said inducing immune tolerance to said replacement therapy comprises reducing neutralizing antibodies to said therapeutic protein. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein which equivalents are intended to be encompassed by the scope of the following claims.

[0040] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference herein. EXAMPLES

[0041] Example 1 - Isolation and optimization of the CD40L-specific Tn3 protein Tn3 is a small protein scaffold approximately 90 amino acids long that has an immunoglobulin-like fold, including loops structurally similar to the complementarity-determining regions of antibodies that can be randomized to select for specific binding properties ( 24 ).

[0042] Human CD40L-specific Tn3 clones were isolated as described in detail in WO 2013 / 055745 (see also 24, 27, 50). Briefly, the selection of human CD40L-specific Tn3 involved five rounds of panning alternating between recombinant human CD40L protein and human CD40L-expressing CHO cell line selection. Mouse CD40L-specific Tn3 protein was selected using recombinant mouse CD40L protein only. Tn3 genes from the selected output were pool cloned into an expression vector and individual His-tagged variants were assessed for CD40L binding by capturing on anti-His antibody-coated Maxisorp plates (2 μg / ml in PBS). Biotinylated MegaCD40L (Enzo Biosciences, 0.5 μg / mL) was added and incubated for 1.5 h. After washing once with PBS / Tween, SA-HRP (1:1000 dilution) was used to monitor the interaction between the captured Tn3 variants and CD40L. After 20 min, the plates were washed twice with PBS / Tween, developed with TMB substrate and stopped with 2.5 M H3PO4. Absorbance was measured at 450 nm. Affinity maturation of CD40L-specific Tn3 protein was performed by selecting improved candidates from a phage-displayed library in which the CDR-like loops were randomly mutated (24). This strategy resulted in the generation of clone 342 (Figure 19), an improved variant of human CD40L-specific 309 (Figure 21A), and clone M31, an improved variant of mouse CD40L-specific M13. Additional human CD40L-Tn3 clones were also prepared, such as clones 304, 311, 320, 310, 321 and 322. See WO 2013 / 055745, which is incorporated herein by reference.

[0043] This set of human CD40L-specific Tn3 clones was characterized for their ability to biochemically inhibit CD40L binding to its receptor (CD40). All seven of this set inhibited CD40L binding to CD40 with IC50 values ​​below 1 μM (Figure 1A). The two most potent inhibitors in the biochemical CD40L-CD40 inhibition assay were further evaluated for inhibition of CD40L-mediated signaling in a cell-based reporter assay. HEK-293 cells expressing human CD40 and an NF-kB-luciferase reporter gene were stimulated with recombinant human CD40L protein. Human CD40L-specific Tn3 proteins 309 and 311 dose-dependently inhibited CD40L-induced NF-kB reporter gene expression at micromolar concentrations (Figure 1B), highlighting the ability of these proteins to functionally inhibit CD40 / CD40L signaling.

[0044] Binding to multiple targets simultaneously, as occurs with bivalent antibodies, can result in significantly increased avidity. To investigate the effect of bivalency on the potency of CD40L-specific Tn3 proteins, two copies of the same Tn3 module (309-309, e.g., FIG. 21B) were linked via a flexible Gly4Ser containing spacer to form a tandem bivalent fusion protein. Human primary B cells upregulate the activation marker CD86 in response to stimulation with CD40. Preincubation of human peripheral blood mononuclear cells (PBMCs) with monovalent CD40L-specific Tn3 309 inhibited the upregulation of CD86 on human CD19+ B cells in a dose-dependent manner (FIG. 1C). Strikingly, primary cell assays using the bivalent construct showed an almost 1000-fold increase in potency compared to monovalent Tn3 (FIG. 1C). In addition, affinity maturation of clone 309 (by random mutagenesis in the variable CDR-like loop regions), resulting in clone 342, demonstrated a significant improvement in binding affinity to CD40L (309: 190 nM, 342: 1.4 nM) and an approximately 300-fold increase in potency in inhibiting the CD40-CD40L interaction (Figure 1D). Affinity matured clone 342 was also screened for binding to a panel of related TNF family members, including Fas, TNFα, TNFβ, and OX40L, and was found to selectively bind CD40L. See Figure 1E.

[0045] Finally, similar to other alternative scaffold technologies, naked Tn3 molecules are expected to exhibit very rapid clearance from the blood circulation when administered systemically due to their small size. To improve the pharmacokinetic properties of this protein, the CD40-specific Tn3 protein was fused to serum albumin (28, 29). M13-M13, a bivalent mouse alternative CD40L-specific Tn3 protein, had a half-life of <30 min when delivered systemically in mice. Fusing mouse serum albumin (MSA) to the M13-M13 Tn3 protein resulted in a 65-fold increase in serum half-life and a 345-fold decrease in clearance (Table 1).

[0046] [Table 1]

[0047] Five- to seven-week-old CD-1 mice were injected with a single dose of bivalent CD40L-specific Tn3 molecules (n=12 / group, 10 mg / kg, iv) with or without MSA. Blood was collected from n=3 mice / group at various time points from 15 min to 72 h, and blood levels of Tn3 protein were measured by ELISA.

[0048] Based on these observations, a bivalent human CD40L-specific Tn3 molecule, VIB4920, is composed of tandem 342 CD40L-specific Tn3 proteins to optimize potency and is fused to human serum albumin (HSA) to improve half-life (Figure 1F, Figure S18).

[0049] To better understand the molecular nature of the interaction between CD40L and VIB4920, crystallographic studies were performed. CD40L-specific Tn3(342) and soluble CD40L proteins were expressed, purified and co-crystallized, and the structure was measured at 2.8 Å resolution. The molecular structure of trimeric soluble CD40L complexed with Tn3 is shown in Figure 2A. The interface with CD40L is mainly composed of amino acids from the second modified loop of Tn3, including 8 of the 10 hydrogen bonds formed intermolecularly (within a distance of 3.5 Å, Figure 2B). Initial characterization of the molecule showed that 342 Tn3 is able to block the interaction between CD40L and CD40. To visualize the details of its action, the structure of the CD40 / CD40L complex was superimposed with that of 342 / CD40L (Figure 1G). The superposition reveals that 342 and CD40 share a common binding site on CD40L. Thus, VIB4920 competes with CD40 and prevents the association of CD40 with CD40L.

[0050] Example 2 - VIB4920 blocks human B cell activation and differentiation CD40 signaling has been extensively characterized and involves the activation of a variety of different pathways and transcription factors, including NF-kB (30), which can promote B cell activation, proliferation, and differentiation (31). Therefore, we investigated the ability of VIB4920 to inhibit CD40L-mediated activation of NF-kB using a cell line expressing human CD40 and an NF-kB luciferase reporter gene. Activation of NF-kB was induced by stimulating this cell line with recombinant human CD40L or CD40L-expressing cells. VIB4920 was able to potently block CD40 signaling using this cell line, as evidenced by a dose-dependent inhibition of NF-kB activation (IC50: 0.899 nM, Figure 3A).

[0051] Resting B cells constitutively express low levels of the costimulatory molecule CD86, which is rapidly upregulated after activation, including activation with CD40 (32). Primary human PBMCs were stimulated with recombinant human CD40L, and expression of CD86 on B cells was assessed 16 h later by flow cytometry. VIB4920 completely blocked CD40L-mediated upregulation of CD86 by primary human B cells (Figure 3B).

[0052] Example 3 - VIB4920 does not induce platelet aggregation in vitro Anti-CD40L-directed mAbs have failed in clinical trials due to safety concerns, primarily due to thromboembolic complications associated with cross-linking of CD40L on the cell surface of platelets. To confirm that VIB4920 lacking the Fc domain does not induce platelet aggregation, we evaluated its effect on washed human platelets in vitro. As previously described, anti-CD40L mAb (human IgG1) showed a remarkable ability to induce platelet aggregation when precomplexed with sCD40L (Figure 3F). The reaction was rapid, with mAb-sCD40L immune complexes inducing 80% of platelets to aggregate within 8 min. Importantly, preincubation of platelets with an antibody blocking FcγRIIa (mAb IV.3) prevented mAb-immune complex-mediated aggregation, consistent with an essential role of Fc receptors in this reaction (Figure 3F). In contrast, at several concentrations tested, VIB4920 showed no tendency to induce platelet aggregation in this assay (Figure 3G). These data suggest that the absence of an Fc region in the Tn3 construct may reduce the risk of platelet aggregation and thromboembolic events observed with therapeutic anti-CD40L antibodies in the clinic. Confirming this result, data from a chronic (7 month) study in non-human primates administered VIB4920 at doses up to 300 mg / kg (not shown) showed no adverse findings in platelet function, e.g., D-dimer assays (to monitor for thrombi), PFA100 assays (to assess platelet function), or TAT complex (thrombin-antithrombin complex) assays.

[0053] Example 4 - CD40L-specific Tn3 protein regulates immune responses in vivo The central role of CD40L in promoting T-dependent immune responses has been well characterized (9, 35). Therefore, we used a T-dependent immune model to evaluate the ability of the Tn3-MSA fusion protein to block humoral immune responses in vivo. Due to insufficient sequence homology between human and mouse CD40L, we used M31, a CD40L-specific murine surrogate Tn3, for these studies.

[0054] To verify whether Tn3-MSA fusion protein can block immune responses in vivo, mice were inoculated with sheep red blood cells (SRBCs) and then treated daily with anti-CD40L Tn3 protein on days 9–13 after inoculation. The immune response of treated animals was evaluated on day 14 by quantifying germinal center B cells in the spleen and lymph nodes by flow cytometry. As expected, immunization of control-treated mice with SRBCs led to a marked expansion in the frequency of germinal centers (Figure 4A). A dose-dependent decrease in the frequency of germinal center B cells was observed in mice treated with CD40L-specific Tn3-MSA fusion protein (Figure 4A). CD40L-specific Tn3-MSA fusion protein induced a complete suppression of germinal center formation, as assessed by the near absence of germinal center B cells in the spleen and lymph nodes, comparable to control non-immunized mice at a dose of 30 mg / kg. Drug administration did not perturb other subpopulations of cells, including specific T cell populations, ensuring that the observed effects were not secondary to T cell depletion (data not shown). In addition, anti-SRBC IgG levels reflected the level of embryonic B cell responses, with SRBC-specific Ig titers significantly reduced at higher doses of anti-CD40L Tn3 (Fig. 4B).

[0055] Example 5 - VIB4920 is well tolerated in healthy volunteers The safety profile of VIB4920 was evaluated in humans in a Phase 1a (Ph1a) study conducted in healthy adults aged 18-49 years. Subjects were randomized to VIB4920 or placebo in seven single ascending dose cohorts with doses of VIB4920 up to 3000 mg (Figures 5A and 5B). The primary endpoint, safety and tolerability, was measured by the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs). Across all dose cohorts, TEAEs were generally mild in clinical severity, with the most frequent events including nasopharyngitis (common cold) and headache (Table 2).

[0056] [Table 2]

[0057] Most common TEAEs occurring in at least two subjects in healthy volunteer Phase 1a studies

[0058] Importantly, the overall proportion of subjects with one or more study drug-related TEAEs was comparable between the overall VIB4920 (40.9%) and placebo (33.3%) groups. In addition, there were no infusion reactions, serious infections, or deaths, and only one TESAE, a tibial fracture, was reported in the placebo group. Of note, no clinically significant coagulation or platelet function abnormalities were observed following treatment with VIB4920 in this Phase 1a study.

[0059] Example 6 - VIB4920 exhibits a favorable PK / PD profile in healthy volunteers In addition to evaluating the safety profile of VIB4920, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints were also evaluated in the Phase 1a study. The PK profile of VIB4920 following single intravenous doses of 3-3000 mg was linear and dose proportional with increasing exposure (Figure 6A). The mean terminal half-life of the molecule was 8 days, with the highest dose resulting in a half-life of up to 10.1 + / - 1.87 days.

[0060] CD40L is a transmembrane protein, but can be cleaved and shed by both activated T cells and platelets. Soluble CD40L (sCD40L) is an 18 KDa trimer that is detected at low levels in healthy donors and is increased in the circulation of patients with autoimmune diseases (36, 37). Measurement of sCD40L levels after VIB4920 administration represents a measure of potential target binding, as VIB4920-bound sCD40L may be retained and accumulated in the circulation. As expected, there was a dose-dependent increase in plasma total sCD40L after VIB4920 administration (Figure 6B), suggesting target binding. The time to reach maximum plasma total sCD40L increased from 11.5 to 84 days as the dose increased from 3 mg to 3000 mg, indicating that target binding was maintained for a longer duration in the highest dose group.

[0061] Example 7 - Decreased ADA was observed in healthy subjects receiving higher doses of VIB4920 Although biologics are by nature highly specific / selective, they are complex molecules capable of eliciting immune responses. Anti-drug antibodies (ADA) are an indicator of the immunogenicity of a therapeutic agent. In healthy volunteers, ADA was detected in the majority of patients receiving low doses of VIB4920 (Figure 7). More specifically, in the dose range of 3-100 mg, 18 of 20 subjects had detectable ADA, with 10 of those individuals exhibiting high ADA titers (greater than the median titer of 480). In contrast, the frequency of ADA was significantly reduced at higher dose levels of VIB4920 (Figure 7), with only 1 of 8 subjects in the 3000 mg dose group developing detectable anti-drug titers. The reduced ADA frequency observed with higher doses of VIB4920 supports the immunomodulatory function of the molecule. In addition, the low rate and titers of ADA may translate into a better tolerated and more effective therapeutic agent.

[0062] Example 8 - VIB4920 inhibits T cell-dependent antibody responses in healthy volunteers VIB4920 was further evaluated for its ability to affect humoral immune responses in healthy subjects by measuring the effect of VIB4920 on T-cell dependent antibody responses (TDAR) induced by immunization with keyhole limpet hemocyanin (KLH). Healthy subjects in all treatment groups received two subcutaneous immunizations of KLH: (1st) 14 days before and (2nd) 15 days after administration of either VIB4920 or placebo (Figure 5B). Both IgM and IgG antibodies produced against KLH were monitored out to day 113.

[0063] The TDAR followed the expected trend in placebo-treated subjects, including a sharp increase in anti-KLH IgG titers on day 22 (1 week after the second immunization), peak levels of IgG observed on day 29, followed by a decline in KLH-specific IgG antibodies until the end of the monitoring period (Figure 8A). Moreover, consistent with previous reports, the second anti-KLH response in the placebo-treated group was dominated by IgG, and the increase in KLH-specific IgM detected after rechallenge was, overall, much more modest (Figure 8B) (38-41).

[0064] As expected, healthy volunteers treated with low doses of VIB4920 had anti-KLH titers close to those of the placebo-treated group. In contrast, healthy volunteers treated with higher doses of VIB4920 showed significantly reduced secondary responses to KLH, as shown by a statistically significant reduction in anti-KLH IgG at day 43 starting with a dose of 300 mg (p=0.035) and increasing to doses of 1,000 mg (p=0.002) and 3,000 mg (p<0.001). Notably, IgG to KLH was reduced by 78% and 86%, respectively, in the 1000 mg and 3000 mg cohorts compared to placebo at day 43 (Figure 8C). In the highest dose group, seven of eight subjects had undetectable anti-KLH-IgG titers at day 43, suggesting an almost complete suppression of humoral immune responses by VIB4920.

[0065] Example 9 - VIB4920 immunosuppression is mediated by inhibition of B cell proliferation and plasma cell responses The mechanism by which VIB4920 suppresses the secondary immune response was further clarified by collecting peripheral blood from subjects before and after immunization and characterizing circulating lymphocyte subsets by flow cytometry. In healthy subjects treated with placebo, secondary immunization induced B cell proliferation, as demonstrated by detecting an increased frequency of circulating Ki67+CD19+ B cells at visit day 22, 7 days after rechallenge (Figure 9A).

[0066] Subjects receiving a high dose of VIB4920 prior to rechallenge had a reduced incidence of baseline B cell proliferation compared to the placebo-treated group, consistent with the proposed mechanism of action of the molecule. Furthermore, the cohort receiving high dose VIB4920 had a significantly impaired B cell proliferative response following immunization, as evidenced by a lack of increase in Ki67+ B cells, see the 3000 mg cohort 1 week postchallenge (Figure 9A). Further phenotypic examination revealed that the greatest impact of VIB4920 on B cell proliferation was observed within the IgD-CD27+ isotype-switched memory population (Figure 9B). These data are consistent with the TDAR results showing an inhibitory effect of VIB4920 on IgG production in response to a second challenge.

[0067] We also monitored changes in gene expression in the peripheral blood of subjects treated with placebo or VIB4920 before and after secondary immunization with KLH. Specifically, we identified specific changes in gene expression using the plasma cell (PC) gene signature (42), an accurate and robust signature capable of detecting even small changes in PC expression frequency in circulating blood. Consistent with the TDAR results, immunization induced a dramatic increase in the PC gene signature score in whole blood of placebo-treated subjects 1 week after rechallenge, which returned to baseline by 2 weeks (Figure 9C). In the highest dose cohort of VIB4920 (3000 mg), the PC gene signature score in peripheral blood was significantly decreased compared to placebo-treated subjects before rechallenge with KLH (Figure 9C). Importantly, volunteers who received the high dose of VIB4920 did not experience an increase in the PC gene signature score after reimmunization. These data shed light on the mechanism of action of VIB4920 and demonstrate its potent ability to suppress B cell and PC responses.

[0068] Example 10 - Repeated Doses of VIB4920 are Safe and Well Tolerated in RA Patients Having established that VIB4920 has an acceptable safety profile and demonstrates mechanism of action validation, repeated titration, and proof of concept in healthy volunteers, a Ph1b clinical trial was conducted in adult patients with moderately to severely active RA. RA patients were treated with VIB4920 (75 mg, n=8; 500 mg, n=10; 1000 mg, n=12; or 1500 mg, n=12), or placebo (n=15), administered by intravenous (iv) infusion every other week for 12 weeks (Figure 10). Patients were then observed for an additional 12 weeks after treatment. Primary endpoints measured at week 12 included safety, tolerability, PK parameters, ADA, and change in disease activity (DAS28-CRP), as well as additional biomarkers such as RF autoantibodies, serum C-reactive protein (CRP), and Vectra-DA score. Fifty-three patients completed 12 weeks of treatment, two patients (one in the VIB4920 75 mg group and one in the VIB4920 1500 mg group) discontinued treatment due to adverse events, one patient in the placebo group withdrew informed consent, and one patient in the VIB4920 75 mg group was lost to follow-up. The main demographic and clinical characteristics of the baseline study population are shown in Figure 11.

[0069] Overall, VIB4920 was generally safe and well tolerated, with a balanced distribution of TEAEs observed between placebo and the four active dose groups. The most common TEAEs reported were diarrhea, hyperhidrosis, upper respiratory tract infection, and urinary tract infection, each occurring in three patients (7.1%). See Figure 12. There were no thrombotic adverse events or clinically significant coagulation abnormalities. One adverse event (preferred term "encephalitis") was reported as serious and life-threatening, occurring in the 1500 mg dose group after six doses of study drug. No etiologic infectious agent was identified, and similar symptoms recurred several months after discontinuing VIB4920, after which the patient was diagnosed with metastatic melanoma of the brain.

[0070] Example 11 - VIB4920 exhibited a linear PK profile and dose-dependently reduced ADA in RA patients ADA was observed in RA patients receiving low doses of VIB4920 as well as in healthy Ph1a study volunteers receiving low doses of VIB4920. Three of eight RA patients receiving 75 mg VIB4920 (37.5%) and three of ten RA patients receiving 500 mg VIB4920 (30%) developed ADA (Figure 13B). In the 75 mg VIB4920 dose group, two of eight subjects developed detectable ADA during the treatment phase, and all three subjects in the 500 mg VIB4920 treatment group developed detectable ADA after treatment (Figure 13C). In the 1000 mg dose group, no ADA was detected during the treatment period, and one subject had detectable ADA after the treatment phase. No ADA was detected in the 1500 mg dose group (Figure 13B), suggesting that VIB4920 effectively suppresses ADA responses at higher doses.

[0071] Example 12 - VIB4920 reduces disease activity in RA patients To determine whether VIB4920 reduces disease activity in RA patients in a Phase 1b clinical trial, the DAS-28 / CRP score was measured. The DAS-28 / CRP score is a composite clinical disease activity score used in RA that takes into account swollen joint counts, tender joint counts, CRP levels, and a patient's global assessment. At higher doses, VIB4920 significantly reduced disease activity in RA patients as quantified by the DAS28-CRP score (Figure 14A and Figure 22A). The adjusted mean change (SE) from baseline in DAS28-CRP at 12 weeks after the start of treatment was -2.3 (0.3) in the VIB4920 1500 mg group, -2.2 (0.3) in the VIB4920 1000 mg group, -1.2 (0.3) in the VIB4920 500 mg group, 0.1 (0.4) in the VIB4920 75 mg group, and -1.0 (0.3) in the placebo group (Figure 14A). Surprisingly, this observed reduction in DAS28-CRP scores in RA patients was maintained for at least another 12 weeks after the last dose of VIB4920 was administered (Figure 22A, see especially visits 113, 141, and 169). The effect of VIB4920 on DAS28-CRP was rapid, with reductions in scores evident as early as 15 days after a single dose of the drug.

[0072] Furthermore, the reduction in disease activity at the two highest doses of VIB4920 was clinically and statistically significant compared to placebo, with adjusted mean differences (SE) at week 12 of -1.4 (0.4) for the VIB4920 1500 mg group and -1.2 (0.4) for the VIB4920 1000 mg group, with p values ​​of 0.002 and 0.006, respectively. Using a linear dose-response model, a statistically significant dose response for DAS28 CRP was shown (p<0.001). Significant results were primarily driven by the 1000 mg and 1500 mg treatment groups, while 500 mg and 75 mg showed little or no effect compared to placebo (Figure 15A). With regard to individual clinical responses, 75% of patients in the 1500 mg group and 50% of patients in the 1000 mg dose group achieved a DAS28-CRP score of 3.2 or less at week 12, indicating low disease activity or clinical remission in the primary endpoint. See Figure 16.

[0073] Example 13 - VIB4920 reduces immunological and inflammatory biomarkers in RA patients The effect of VIB4920 on immunological and inflammatory biomarkers was measured using the Vectra DA blood test, a commercially available, validated test that measures 12 biomarkers of disease activity (cell adhesion molecules, growth factors, cytokines, matrix metalloproteinases, skeletal proteins, hormones, and acute phase proteins) and combines them into a single score to assess the key mechanisms and pathways driving RA disease activity. VIB4920 at 1500mg and 1000mg doses significantly reduced the Vectra DA multi-biomarker score during both the 12-week period when VIB4920 was administered every other week (Figure 14E) and the 12-week observation period when VIB4920 was no longer administered (Figure 22E). The adjusted mean difference (week 12) for VIB4920 at the 1500 mg dose compared to placebo was -14.4 (-21.5, -7.2), p=0.001, and the adjusted mean difference (week 12) for VIB4920 at the 1000 mg dose compared to placebo was -10.3 (-17.4, -3.3), p=0.018 (Figure 14E).

[0074] These efficacy results were highly consistent across other endpoints evaluated in the study, including Clinical Disease Activity Index (CDAI), tender and swollen joint counts, patient and physician global assessments, and serum CRP levels, supporting the study's finding that 1000 mg and 1500 mg are clinically efficacious doses (see also Figures 14B-14D and Figures 17A-17C, Figures 22B-22D, and Figures 23A-23C).

[0075] Example 14 - VIB4920 Significantly Reduces Rheumatoid Factor Autoantibodies in RA Subjects Rheumatoid factor autoantibodies (RF) are a family of autoantibodies raised against the Fc portion of IgG. They are increased in RA and associated with poor prognosis. Given the mechanism of action of VIB4920, its impact on autoantibody titers in RA subjects was evaluated. Remarkably, VIB4920 significantly reduced RF titers at the 500, 1000, and 1500 mg dose levels during the 12-week biweekly treatment period (Figure 14F). Even more surprisingly, the reduced RF titers at the 1000 mg and 1500 mg dose levels were maintained throughout the 12-week observation period after the last dose of VIB4920 was administered (Figure 22F). Reductions in RF titers from baseline were evident in response to VIB4920 as early as day 29, with the higher dose of VIB4920 reducing RF titers by approximately 50% by day 85. Using the Emax model, VIB4920 shows a statistically significant dose response in terms of reduction in RF titers from baseline (p<0.001) (Figure 15B).

[0076] Example 15 - Methods NF-kB reporter assay HEK293 cells (Panomics) expressing an NF-kB luciferase reporter were engineered to stably express human full-length CD40R. 4 Cells were seeded into 96-well poly-D-lysine-coated plates (BD Biosciences) at a density of 100 cells / well and stimulated with megaCD40L recombinant protein (1.5 μg / ml, Enzo Biosciences) or D1.1 Jurkat subclone (ATCC) cells overexpressing CD40L at the indicated concentrations in the presence or absence of control or CD40L-specific Tn3 for 16–24 h. Luminescence was detected on a SpectraMax M5 plate reader (Molecular Devices) using the Bright-Glo Luciferase Assay System (Promega).

[0077] CD86 upregulation assay Human blood was collected from healthy donors after informed consent as approved by MedImmune's Institutional Review Board. Peripheral blood mononuclear cells were isolated from CPT tubes (BD Biosciences) after centrifugation. PBMCs (2.5–5.0 × 10 ) were cultured with recombinant megaCD40L (100 ng / ml, Enzo Biosciences) in 96-well round-bottom plates for 16–18 h in the presence of CD40L-specific Tn3 or mAb (clone 5c8) as indicated. 5 Cells (cells / well) were stimulated with 100 µg / mL of IgG19+ B cells. Flow cytometry was used to assess the expression of CD86 on CD19+ B cells. The following antibodies were used: CD86 (clone 2331, BD Pharmingen), CD19 (clone HIB19, BD Pharmingen).

[0078] Human B cell assay PBMCs were isolated. Total B cells were negatively selected using MACS cell separation technology (Miltenyi Biotec), which routinely yielded a purity of >95%. Purified peripheral blood B cells were plated at 0.5–1.0 × 10 B cells per well in 96-well round-bottom plates in a final volume of 150 μl complete medium. 5The cells were cultured at a density of 100 μg / ml. The medium for B cell experiments was RPMI 1640 (Invitrogen) supplemented with 10% FCS, penicillin-streptomycin (100 units / ml penicillin, 100 μg / ml streptomycin), 2-mercaptoethanol (55 μM), L-glutamine (2 mM), and HEPES (5 mM). At the initiation of culture, B cells were stimulated with a combination of IL-21 (33 ng / ml, PeproTech Inc.) and megaCD40L (1.5 nM, Enzo Biosciences) with or without anti-IgM F(ab')2 (5.0 μg / ml, Jackson ImmunoResearch Laboratories). On the third or fourth day of culture, B cell proliferation was quantified by measuring ATP using the Cell Titer-Glo Luminescent Assay (Promega) according to the manufacturer's instructions. PC differentiation was quantified by flow cytometry on day 7. Cells were obtained over time and PCs were identified as CD19+IgD-CD38 hi It was defined as a cell.

[0079] Mouse SRBC immunization model Balb / c mice (Jackson Laboratories) were immunized on day 0 with 0.2 ml of SRBCs (Colorado Serum Company) by intraperitoneal injection after direct withdrawal from the bottle. Control (30 mg / kg) or CD40L-specific Tn3 (up to 30 mg / kg, as indicated) was administered daily (intravenously) on days 9-13. On day 14, the frequency of splenic germinal center B cells was quantified by flow cytometry. GC B cells were identified as CD19 + B220 + Fas + PNA + were defined as B cells.

[0080] Platelet aggregation assay Human blood was collected from healthy donors and placed into ACD solution B tubes containing citrate, glucose, and sodium. After centrifugation, 2 / 3 of the platelet-rich plasma was transferred to a polypropylene tube and incubated with apyrase (2 U / ml) for 10 min to prevent platelet activation during processing. Platelets were pelleted and resuspended in modified Tyrode's buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM glucose, 3.3 mM NaH2PO4, 20 mM HEPES, 0.1% BSA, and pH 7.4).

[0081] Immune complexes (IC) were generated by mixing mAb (h5c8, or negative control antibody) or anti-CD40L Tn3 with hCD40L (293 Cell Source) for 5 min at room temperature. In some experiments, platelets were preincubated with anti-CD32a antibody (IV.3) for 5 min before adding IC. Platelet aggregation assays were performed according to the manufacturer's instructions in a four-channel optical platelet aggregometer (Model 700, Chrono-Log, Havertown, PA) with stirring at 37 °C. After mixing washed platelets with agonist, light transmission was monitored for 12–20 min.

[0082] Phase 1a subjects and study design A randomized, blinded, placebo-controlled phase I study was conducted in healthy adults aged 18-49 years, including women of non-childbearing potential (NCT02151110). Based on the study protocol, which considered the accumulated data from previous dose cohorts as well as the safety and tolerability data from the current dose cohort, and recommendations from the Dose Escalation Committee (DEC), subjects were randomized into seven dose cohorts (3, 10, 30, 100, 300, 1000, or 3000 mg) and administered sequentially. Subjects were induced to TDAR by subcutaneous immunization with two 1 mg doses of KLH. The first KLH immunization was administered during a screening period 14 days before administration of either VIB4920 or placebo, and the second KLH immunization was administered 15 days after administration of either VIB4920 or placebo. Three interim analyses were performed according to the protocol when all subjects in cohort 5 (300 mg), cohort 6 (1000 mg), and cohort 7 (3000 mg) had completed treatment on day 43, respectively.

[0083] PK assay of VIB4920 A validated sandwich ELSA method was used to measure VIB4920 in human K2EDTA plasma, where a washing step with 1x PBS / 0.1% Tween 20 (PBST) was performed after each incubation to remove unbound components. Briefly, Nunc microtiter plates were coated with 1 μg / mL anti-VIB4920 mouse monoclonal antibody (MedImmune) overnight at 2-8°C. Standards, quality controls (QCs), and samples containing VIB4920 were diluted in 0.5% bovine serum albumin (BSA) / PBST in a minimum dilution factor (MRD) manner of 1:50 before being added to the plate. After 2 hours of incubation, 1 μg / mL of biotinylated anti-VIB4920 rat antibody (MedImmune) was added to the plate and incubated for 1 hour. Binding complexes were visualized by sequential incubation with streptavidin-conjugated horseradish peroxidase (HRP, GE Healthcare) and SureBlue™ tetramethylbenzidine (TMB) peroxidase substrate (KPL, Inc.). Color development was stopped with 0.2 M sulfuric acid before analysis at 450 nm in a microplate reader. The quantitative range was 0.05-1.60 μg / mL; samples with measurements above the quantitative range were diluted with pooled K2EDTA plasma to bring concentrations within the measurable range of the method.

[0084] Quantification of sCD40L Plasma samples were collected to measure sCD40L concentrations during the screening period and on days 1, 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113. Total soluble CD40L (free sCD40L and sCD40L bound to VIB4920) was measured in human K2EDTA plasma using a human sCD40L Platinum ELISA kit (eBioscience), modified to fit the needs of the program and qualified to ensure accuracy and precision. In summary, standards, QCs, and samples containing sCD40L were diluted in 0.5% BSA / PBST and VIB4920-containing assay diluent in a 1:50 MRD manner to ensure comparable and consistent results. A washing step with PBST was performed after each incubation to remove unbound components. The diluted samples were added to plates precoated with anti-sCD40L antibody and incubated for 1.5 hours. HRP-conjugated anti-human sCD40L was then added and allowed to bind to the sCD40L captured by the coated antibody. The bound complex was visualized by the sequential addition of TMB peroxidase substrate and stop solution (phosphate) before analysis at 450 nm and 540 nm in a microplate reader. The quantitative range was 6.25-400.00 ng / mL; samples with measurements above the quantitative range were diluted with pooled K2EDTA plasma to bring the concentration within the measurable range of the method.

[0085] Measurement of ADA A validated sandwich ELISA method was used to measure the presence of ADA to VIB4920 in human K2EDTA plasma, where a washing step with PBST was performed after each incubation to remove unbound components. Briefly, QC and samples were diluted in assay diluent containing 0.5% BSA / PBST by the method of MRD 1:60 and added to washed Pierce™ Protein G coated plates (ThermoFisher) and incubated for 2 hours. ADA to VIB4920 was specifically detected by overnight incubation of 1 μg / mL biotinylated VIB4920 prepared in assay diluent. Binding complexes were visualized by sequential incubation with streptavidin-conjugated HRP (GE Healthcare) and SureBlue™ TMB peroxidase substrate (KPL, Inc.). Color development was stopped with 0.2 M sulfuric acid before analysis at 450 nm in a microplate reader. Each sample was subjected to a three-step process in which the sample response was first compared to a statistically determined cut-off OD value above which the sample was considered potentially ADA positive and below which the sample was deemed ADA negative. Potentially positive samples were subjected to a second competitive evaluation in the presence of good VIB4920. Samples with inhibition rates equal to or greater than the statistically determined confirmation cut-point were defined as confirmed positive and were evaluated for titer. Samples below the confirmation cut-point were considered negative for ADA to VIB4920. Titer samples in pooled human K2EDTA plasma were serially diluted until below the screening cut-off and titer results were reported as the reciprocal of the highest dilution at which the sample tested positive before testing negative.

[0086] Evaluation of anti-KLH antibodies Anti-Keyhole Limpet Hemocyanin (KLH) IgG antibodies were measured in human serum using a validated sandwich ELISA method, where a washing step with PBST was performed after each incubation to remove unbound components. A volume of 100 μL / well was used for all steps. Briefly, nunc microtiter plates were coated with 3 μg / mL KLH (Immucothel, biosyn Arzneimittel GmbH) prepared in 1× PBS (pH 7.2) overnight at 2–8°C. Standards and QCs consisting of a mixture of nine monoclonal anti-KLH IgG antibodies with various isotypes and affinities (AstraZeneca) and samples containing anti-KLH antibodies were diluted in 0.5% BSA / PBST by the method according to MRD of 1:250 before addition to the plates. After 2 h of incubation, HRP-conjugated mouse anti-human IgG (Invitrogen) was added to the plate and incubated for 1 h to specifically detect anti-KLH IgG antibodies. Binding complexes were visualized by sequential addition of TMB peroxidase substrate and stop solution (0.2 M sulfuric acid) before analysis at 450 nm in a microplate reader. The quantitative range was 163.30-10000.00 ng / mL. Samples with measurements above the quantitative range were diluted with serum to bring the concentration within the measurable range of the method.

[0087] Flow cytometry in Ph1a Blood was collected into Cytochex BCT tubes (Streck) and shipped to Covance Central Laboratory Services (Indianapolis, IN) for testing by flow cytometry using validated methods. Briefly, cells were stained with fluorochrome-conjugated antibodies against CD45 (clone HI30), CD19 (clone HIB19), IgD (clone IA6-2), CD27 (clone M-T271), and CD38 (clone HIT2, all BD) to identify B cell populations. Cells were then treated with FACSPerm2 (Becton Dickenson) and stained for intracellular Ki67 (clone KI67, Biolegend) expression to measure proliferating cells.

[0088] PC Signature PC gene signatures were measured as previously described (Streicher 2014). Briefly, total RNA was extracted from PAXgene blood collection tubes using the PAXgene Blood RNA kit (Qiagen). cDNA for TaqMan qPCR was generated using the SuperScript III First-Strand Synthesis SuperMix kit (Life Technologies) and random primers. Samples were prepared using the TaqMan Pre-Amp Master Mix kit and analyzed on a BioMark Real-Time PCR System. We calculated ΔΔCt values ​​using two reference genes (β-actin and GAPDH) and the mean baseline expression levels of each patient as a control. Fold change values ​​were determined by calculating 2-ΔΔCt.

[0089] Phase 1a patients and study design We conducted a phase Ib randomized, blinded, placebo-controlled study in patients aged 18-70 years who were diagnosed with RA according to EULAR / ACR criteria (Aletaha et al. 2010) for at least 6 months prior to study entry. Subjects had moderate to severe disease activity as defined by a DAS28-CRP score of at least 3.2 at screening and at least 4 swollen joints and 4 tender joints at screening and randomization. Patients were either positive for rheumatoid factor (RF-IgM ≥ 14 units / mL) or anti-citrullinated peptide antibodies (ACPA) at screening. Patients received methotrexate (MTX) at doses of 7.5-25 mg per week or, in case of MTX intolerance, initiated a different conventional DMARD at least 12 weeks prior to screening and at least 6 weeks at a stable dose. Previous treatment with biologics given for RA (except rituximab or other B cell depleting agents) was allowed with appropriate washout prior to randomization in our study. Patients were treated with placebo (n=15) or VIB4920 (75mg n=8; 500mg n=10; 1000mg n=12; or 1500mg n=12) by intravenous infusion every other week for 12 weeks, followed by 12 weeks of post-treatment observation. Measurement of VECTRA-DA scores was performed by Crescendo Bioscience (San Francisco, CA), and measurement of RF autoantibodies was performed by Covance Central Laboratories Services (Princeton, NJ).

[0090] statistical analysis A two-tailed unpaired Student's t-test was used to evaluate the effect of treatment on primary human B cell proliferation, plasma differentiation, and GC B cell responses in the SRBC model. A Mann-Whitney U test was used to compare VIB4920 to placebo at multiple time points for gene signature scores (Figure 9C). Statistical tests and plots were performed using Graphpad Prism software. Dose-response for change from baseline in DAS28-CRP and RF at day 85 was analyzed using the MCP-Mod method, which has three prespecified candidate models for dose-response (linear, Emax, and Hill-Emax models) and includes the corresponding baseline as a covariate. Tests of dose-response signals were adjusted for multiplicity and controlled the family-wise error rate at the 0.10 level. A final model was selected from among those shown to be significant based on the Akaike information criterion. Changes from baseline in DAS28-CRP, RF, Vectra DA, CDAI, tender joint count, swollen joint count, patient and physician global assessment, and serum CRP were analyzed using mixed-effects model with repeated measures (MMRM) analyses in which corresponding baseline outcomes were included as covariates.

[0091] References cited in this disclosure 1.S.Sugio,A.Kashima,S.Mochizuki,M.Noda,K.Kobayashi,Crystal structure of human serum albumin at 2.5 A resolution.Protein Eng 12,439-446(1999) 2.S.Lederman et al.,Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation(help).The Journal of experimental medicine 175,1091-1101(1992). 3.M.Croft,R.M.Siegel,Beyond TNF:TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Nature reviews.Rheumatology 13,217-233(2017). 4.T.M.Foy,F.H.Durie,R.J.Noelle,The expansive role of CD40 and its ligand,gp39,in immunity.Seminars in immunology 6,259-266(1994). 5.J.B.Splawski,P.E.Lipsky,CD40-mediated regulation of human B-cell responses.Research in immunology 145,226-234;discussion 244-229(1994). 6.R.J.Armitage et al.,Molecular and biological characterization of a murine ligand for CD40.Nature 357,80-82(1992). 7.P.Garside et al.,Visualization of specific B and T lymphocyte interactions in the lymph node.Science 281,96-99(1998). 8.D.Hollenbaugh et al.,The human T cell antigen gp39,a member of the TNF gene family,is a ligand for the CD40 receptor:expression of a soluble form of gp39 with B cell co-stimulatory activity.The EMBO journal 11,4313-4321(1992). 9.R.J.Noelle et al.,A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.Proceedings of the National Academy of Sciences of the United States of America 89,6550-6554(1992). 10.T.M.Foy et al.,gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.The Journal of experimental medicine 180,157-163(1994). 11.T.M.Foy et al.,In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity.II.Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40,gp39.The Journal of experimental medicine 178,1567-1575(1993). 12.S.Han et al.,Cellular interaction in germinal centers.Roles of CD40 ligand and B7-2 in established germinal centers.Journal of immunology 155,556-567(1995). 13.T.Kawabe et al.,The immune responses in CD40-deficient mice:impaired immunoglobulin class switching and germinal center formation.Immunity 1,167-178(1994). 14.R.C.Allen et al.,CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.Science 259,990-993(1993). 15.A.Aruffo et al.,The CD40 ligand,gp39,is defective in activated T cells from patients with X-linked hyper-IgM syndrome.Cell 72,291-300(1993). 16.J.P.DiSanto,J.Y.Bonnefoy,J.F.Gauchat,A.Fischer,G.de Saint Basile,CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.Nature 361,541-543(1993). 17.D.T.Boumpas et al.,A short course of BG9588(anti-CD40 ligand antibody)improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.Arthritis and rheumatism 48,719-727(2003). 18.A.C.Grammer et al.,Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.The Journal of clinical investigation 112,1506-1520(2003). 19.W.Huang et al.,The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.Arthritis and rheumatism 46,1554-1562(2002). 20.V.L.Patel,J.Schwartz,J.B.Bussel,The effect of anti-CD40 ligand in immune thrombocytopenic purpura.British journal of haematology 141,545-548(2008). 21.S.E.McKenzie et al.,The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets:a transgenic mouse model.Journal of immunology 162,4311-4318(1999). 22.J.E.Freedman,CD40-CD40L and platelet function:beyond hemostasis.Circulation research 92,944-946(2003). 23.L.Robles-Carrillo et al.,Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.Journal of immunology 185,1577-1583(2010). 24.J.S.Swers et al.,Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis.Molecular cancer therapeutics 12,1235-1244(2013). 25.R.Vazquez-Lombardi et al.,Challenges and opportunities for non-antibody scaffold drugs.Drug discovery today 20,1271-1283(2015). 26.R.N.Gilbreth,B.M.Chacko,L.Grinberg,J.S.Swers,M.Baca,Stabilization of the third fibronectin type III domain of human tenascin-C through minimal mutation and rational design.Protein engineering,design & selection:PEDS 27,411-418(2014). 27.V.Oganesyan et al.,Fibronectin type III domains engineered to bind CD40L:cloning,expression,purification,crystallization and preliminary X-ray diffraction analysis of two complexes.Acta crystallographica.Section F,Structural biology and crystallization communications 69,1045-1048(2013). 28.D.Muller et al.,Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.The Journal of biological chemistry 282,12650-12660(2007). 29.B.J.Smith et al.,Prolonged in vivo residence times of antibody fragments associated with albumin.Bioconjugate chemistry 12,750-756(2001). 30.I.Berberich,G.L.Shu,E.A.Clark,Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B.Journal of immunology 153,4357-4366(1994). 31.M.Kaileh,R.Sen,NF-kappaB function in B lymphocytes.Immunological reviews 246,254-271(2012). 32.M.Roy et al.,Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses.European journal of immunology 25,596-603(1995). 33.R.Ettinger et al.,IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.Journal of immunology 175,7867-7879(2005). 34.J.L.Karnell et al.,CD19 and CD32b differentially regulate human B cell responsiveness.Journal of immunology 192,1480-1490(2014). 35.B.R.Renshaw et al.,Humoral immune responses in CD40 ligand-deficient mice.The Journal of experimental medicine 180,1889-1900(1994). 36.K.Kato et al.,The soluble CD40 ligand sCD154 in systemic lupus erythematosus.The Journal of clinical investigation 104,947-955(1999). 37.R.K.Vakkalanka et al.,Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera.Arthritis and rheumatism 42,871-881(1999). 38.P.Bird,J.E.Calvert,P.L.Amlot,Distinctive development of IgG4 subclass antibodies in the primary and secondary responses to keyhole limpet haemocyanin in man.Immunology 69,355-360(1990). 39.M.E.Devey,K.M.Bleasdale-Barr,P.Bird,P.L.Amlot,Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin.Immunology 70,168-174(1990). 40.J.Ferbas et al.,A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus.British journal of clinical pharmacology 76,188-202(2013). 41.J.S.Miller et al.,Diminished neo-antigen response to keyhole limpet hemocyanin(KLH)vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation.Clinical immunology 117,144-151(2005). 42.K.Streicher et al.,The plasma cell signature in autoimmune disease.Arthritis & rheumatology 66,173-184(2014). 43.F.J.Dumont,IDEC-131.IDEC / Eisai.Current opinion in investigational drugs 3,725-734(2002). 44.W.Schuler et al.,Efficacy and safety of ABI793,a novel human anti-human CD154 monoclonal antibody,in cynomolgus monkey renal allotransplantation.Transplantation 77,717-726(2004). 45.F.Langer et al.,The role of CD40 in CD40L- and antibody-mediated platelet activation.Thrombosis and haemostasis 93,1137-1146(2005). 46.C.Heeschen et al.,Soluble CD40 ligand in acute coronary syndromes.The New England journal of medicine 348,1104-1111(2003). 47.F.Mach,U.Schonbeck,G.K.Sukhova,E.Atkinson,P.Libby,Reduction of atherosclerosis in mice by inhibition of CD40 signalling.Nature 394,200-203(1998). 48.T.Oura et al.,Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates.American journal of transplantation:official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 12,1740-1754(2012). 49.M.Watanabe et al.,ASKP1240,a fully human anti-CD40 monoclonal antibody,prolongs pancreatic islet allograft survival in nonhuman primates.American journal of transplantation:official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 13,1976-1988(2013). 50.D.Spencer et al.,O-xylosylation in a recombinant protein is directed at a common motif on glycine-serine linkers.J Pharm Sci 102,3920-3924(2013).

Claims

1. 1. A composition for use in a method of treating or preventing an autoimmune disease or disorder in a subject, comprising: the composition comprises a CD40L-specific Tn3 scaffold protein; the method comprises administering to the subject the CD40L-specific Tn3 scaffold protein at a dose of about 1500 mg to 3000 mg; the CD40L-specific Tn3 scaffold protein comprises two monomer sequences and a human serum albumin sequence; Each monomer sequence comprises the polypeptide sequence of SEQ ID NO:3, The composition, wherein the autoimmune disease or disorder is Sjogren's syndrome.

2. 1. A composition for use in a method of treating or preventing an autoimmune disease or disorder in a subject, comprising: the composition comprises a CD40L-specific Tn3 scaffold protein; the method comprises administering to the subject the CD40L-specific Tn3 scaffold protein at a dose of about 1500 mg to 3000 mg; The CD40L-specific Tn3 scaffold protein comprises SEQ ID NO:1, The composition, wherein the autoimmune disease or disorder is Sjogren's syndrome.

3. 3. The composition of claim 1 or 2, wherein the dose is about 1500 mg.

4. 3. The composition of claim 1 or 2, wherein the dose is about 3000 mg.

5. The composition of any of claims 1 to 4, wherein said dosage is administered every 14 days or twice a month.

6. The composition according to any one of claims 1 to 5, wherein the administration is intravenous administration.

7. The composition of any one of claims 1 to 6, wherein said administration is effective to reduce the level of an inflammatory marker.

8. 8. The composition of claim 7, wherein the inflammatory markers comprise one or more of autoantibody levels, plasma cell (PC) signature, circulating B cells, and antibody class switching.

9. The composition of claim 8, wherein the reduction in the level of the inflammatory marker comprises a reduction in the PC signature.

10. 10. The composition of claim 9, wherein the decrease in the PC signature is a decrease in expression of a gene selected from the group consisting of immunoglobulin heavy chain constant region alpha 1 (IGHA1), polymeric IgA and IgM joining chain (IGJ), immunoglobulin kappa constant (IGKC), immunoglobulin kappa variable 4-1 (IGKV4-1), and TNF receptor superfamily member 17 (TNFRSF17).

Citation Information

Patent Citations

  • CD40L-specific Tn3-derived scaffolding and its usage method

    JP2015501147A